

Bl. to correps to EP 952 149

(19)  Canadian Intellectual Property Office

Office de la Propriété Intellectuelle du Canada

(11) CA 2 269 246

(13) A1

(43) 17.10.1999

An Agency of Industry Canada

Un organisme d'Industrie Canada

(12)

(21) 2 269 246

(51) Int. Cl. 6: C07D 209/88, A61K 031/40,
A61K 031/535

(22) 16.04.1999

(30) 09/062,328 US 17.04.1998

VASILEFF, Robert Theodore (US).
BACH, Nicholas James (US).
BASTIAN, Jolie Anne (US).
KINNICK, Michael Dean (US).
MIHELICH, Edward David (US).
HITE, Gary Alan (US).

(71) ELI LILLY AND COMPANY,
Lilly Corporate Center, INDIANAPOLIS, XX (US).

(72) MORIN, John Michael Jr. (US).
SALL, Daniel Jon (US).

(74) Gowling, Strathy & Henderson

(54) TRICYCLIQUES SUBSTITUES
(54) SUBSTITUTED TRICYCLICS

(57)

Novel tricyclics are disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

THIS PAGE BLANK (USPTO)

O P I C
OFFICE DE LA PROPRIÉTÉ
INTELLECTUELLE DU CANADA



C I P O
CANADIAN INTELLECTUAL
PROPERTY OFFICE

(12)(19)(CA) **Demande-Application**

(21)(A1) **2,269,246**
(22) 1999/04/16
(43) 1999/10/17

(72) BACH, Nicholas James, US
(72) BASTIAN, Jolie Anne, US
(72) HITE, Gary Alan, US
(72) KINNICK, Michael Dean, US
(72) MIHELICH, Edward David, US
(72) MORIN, John Michael Jr., US
(72) SALL, Daniel Jon, US
(72) VASILEFF, Robert Theodore, US
(71) ELI LILLY AND COMPANY, US
(51) Int.Cl.⁶ C07D 209/88, A61K 31/535, A61K 31/40
(30) 1998/04/17 (09/062,328) US
(54) TRICYCLIQUES SUBSTITUÉS
(54) SUBSTITUTED TRICYCLICS

(57) Novel tricyclines are disclosed together with the use of such compounds for inhibiting sPLA₂ mediated release of fatty acids for treatment of conditions such as septic shock.



Industrie Canada Industry Canada

X-12143A

Abstract

Novel tricyclics are disclosed together with the
5 use of such compounds for inhibiting sPLA₂ mediated release
of fatty acids for treatment of conditions such as septic
shock.

X-12143A

-1-

SUBSTITUTED TRICYCLICS

This application claims the benefit of U. S.
Serial No. 09/062,328 filed April 17, 1998.

5

This invention relates to novel substituted tricyclic organic compounds useful for inhibiting sPLA₂ mediated release of fatty acids for conditions such as septic shock.

10

The structure and physical properties of human non-pancreatic secretory phospholipase A₂ (hereinafter called, "sPLA₂") has been thoroughly described in two articles, namely, "Cloning and Recombinant Expression of Phospholipase A₂ Present in Rheumatoid Arthritic Synovial

15

Fluid" by Seilhamer, Jeffrey J.; Pruzanski, Waldemar; Vadas Peter; Plant, Shelley; Miller, Judy A.; Kloss, Jean; and Johnson, Lorin K.; The Journal of Biological

Chemistry, Vol. 264, No. 10, Issue of April 5, pp. 5335-5338, 1989; and "Structure and Properties of a Human Non-

20

pancreatic Phospholipase A₂" by Kramer, Ruth M.; Hession, Catherine; Johansen, Berit; Hayes, Gretchen; McGray, Paula; Chow, E. Pingchang; Tizard, Richard; and Pepinsky, R. Blake; The Journal of Biological Chemistry, Vol. 264, No. 10, Issue of April 5, pp. 5768-5775, 1989; the

25

disclosures of which are incorporated herein by reference.


It is believed that sPLA₂ is a rate limiting enzyme in the arachidonic acid cascade which hydrolyzes membrane phospholipids. Thus, it is important to develop compounds which inhibit sPLA₂ mediated release of fatty acids (e.g., arachidonic acid). Such compounds would be of value in general treatment of conditions induced and/or maintained by overproduction of sPLA₂ such as septic shock, adult respiratory distress syndrome, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, etc.

X-12143A

-2-

It is desirable to develop new compounds and treatments for sPLA₂ induced diseases.

Tricyclic compounds effective in inhibiting 5 human sPLA₂ mediated release of fatty acids are depicted in the general formula I below:



wherein;

10 Z is cyclohexenyl, or phenyl,

R²⁰ is selected from groups (a), (b) and (c) where;

(a) is -(C₅-C₂₀)alkyl, -(C₅-C₂₀)alkenyl, -(C₅-C₂₀)alkynyl, carbocyclic radicals, or heterocyclic radicals, or

15

(b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or

20 (c) is the group -(L)-R⁸⁰; where, (L)-is a divalent linking group of 1 to 12 atoms selected from carbon, hydrogen, oxygen, nitrogen, and sulfur; wherein the combination of atoms in -(L)- are selected from the group consisting of (i) carbon and hydrogen only,

25 (ii) one sulfur only, (iii) one oxygen only, (iv) one or two nitrogen and hydrogen only, (v) carbon, hydrogen, and one sulfur only, and (vi) an carbon,

X-12143A

-3-

- hydrogen, and oxygen only; and where R⁸⁰ is a group selected from (a) or (b);
- R²¹ is a non-interfering substituent where f is 1-3;
- R¹ is -NHNH₂, -NH₂, or -CONH₂;
- 5 R² is selected from the group consisting of -OH, and -O(CH₂)_tR⁵ where
- R⁵ is H, -CN, -NH₂, -CONH₂, -CONR⁹R¹⁰, -NHSO₂R¹⁵; -CONHSO₂R¹⁵, where R¹⁵ is -(C₁-C₆)alkyl or -CF₃; phenyl or phenyl substituted with -CO₂H or -CO₂(C₁-C₄)alkyl; and -(L_a)-(acidic group), wherein -(L_a)- is an acid linker having an acid linker length of 1 to 7 and t is 1-5;
- 10 R³ is selected from non-interfering substituent, carbocyclic radicals, carbocyclic radicals substituted with non-interfering substituents, heterocyclic radicals, and heterocyclic radicals substituted with non-interfering substituents; or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt,
- 15 thereof.
- 20 The compounds of Formula I contemplated by this invention are selected from the group consisting of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid, {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid,
- 25 {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid, [9-

X-12143A

-4-

[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or
5 salt thereof.

This invention is also a pharmaceutical formulation comprising a compound selected from the group consisting of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid, {9-[(phenyl)methyl]-5-carbamoyl-carbazol-10 4-yl}oxyacetic acid, {9-[(3-fluorophenyl)methyl]-5- carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-trifluoromethylphenyl)methyl]-5- carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-methylphenyl)methyl]-5- carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid, [9-[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, and [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid in association with one or more pharmaceutically acceptable diluents, carriers and excipients.
15
20
25

This invention is also a method of inhibiting SPLA₂ comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid, {9-[(phenyl)methyl]-5- carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-trifluoromethylphenyl)methyl]-5- carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(2-

X-12143A

-5-

methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-methylphenyl)methyl]-5-

carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-

5 yl}oxyacetic acid, sodium salt, [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid, [9-[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, and [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid.

10 According to a further aspect of the present invention, there is provided a method of selectively inhibiting sPLA₂ in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound selected from the group

15 consisting of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl}oxyacetic acid, {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-fluorophenyl)methyl]-5-

carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-trifluoromethylphenyl)methyl]-5-

20 carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-methylphenyl)methyl]-5-

carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-

25 trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid, [9-[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, and [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic

30 acid.

This invention, further provides a compound selected from the group consisting of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl}oxyacetic acid, {9-[(phenyl)-methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid I, {9-[(3-

X-12143A

-6-

fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid, [9-[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, and [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid for use as a medicament in the treatment of inflammatory diseases such as, septic shock, adult respiratory distress syndrome, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathis, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathic spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infectious arthritis, gonococcal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with "vasculitic syndromes", polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgia rheumatica, joint cell arteritis, calcium crystal deposition arthropathis, pseudo gout, non-articular rheumatism, bursitis, tenosynovitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury (typing), miscellaneous forms of arthritis, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura,

X-12143A

-7-

hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis associated with certain diseases, surcoilosis, hemochromatosis, sickle cell disease and other hemoglobinopathies, hyperlipoproteineimia,

5 hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythrematosis, or relapsing polychondritis and related diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount

10 of the compound of formula I in an amount sufficient to inhibit sPLA₂ mediated release of fatty acid and to thereby inhibit or prevent the arachidonic acid cascade and its deleterious products.

Other objects, features and advantages of the
15 present invention will become apparent from the subsequent description and the appended claims.

Definitions:

As used herein, the term, "alkyl" by itself or
20 as part of another substituent means, unless otherwise defined, a straight or branched chain monovalent hydrocarbon radical such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, isobutyl, sec-butyl, tert butyl, n-pentyl, isopentyl, neopentyl, heptyl, hexyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradearyl and the like. The term "alkyl" includes -(C₁-C₂)alkyl, -(C₁-C₄)alkyl, -(C₁-C₆)alkyl, -(C₅-C₁₄)alkyl, and -(C₁-C₁₀)alkyl.

The term "alkenyl" as used herein represents an
30 olefinically unsaturated branched or linear group having at least one double bond. Examples of such groups include radicals such as vinyl, allyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl,

X-12143A

-8-

5-heptenyl, 6-heptenyl as well as dienes and trienes of straight and branched chains.

The term "alkynyl" denotes such radicals as ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl as 5 well as di- and tri-ynes.

The term "halo" means chloro, fluoro, bromo or iodo.

The term "-(C₁-C₄)alkoxy", as used herein, denotes a group such as methoxy, ethoxy, n-propoxy, 10 isopropoxy, n-butoxy, t-butoxy and like groups, attached to the remainder of the molecule by the oxygen atom.

The term "phenyl(C₁-C₄)alkyl" refers to a straight or branched chain alkyl group having from one to four carbon atoms attached to a phenyl ring which chain is 15 attached to the remainder of the molecule. Typical phenylalkyl groups include benzyl, phenylethyl, phenylpropyl, phenylisopropyl, and phenylbutyl.

The term "-(C₁-C₄)alkylthio" defines a straight or branched alkyl chain having one to four carbon atoms 20 attached to the remainder of the molecule by a sulfur atom. Typical -(C₁-C₄)alkylthio groups include methylthio, ethylthio, propylthio, butylthio and the like.

The term "-(C₃-C₁₄)cycloalkyl" includes groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 25 cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and the like. The term "-(C₃-C₁₄)cycloalkyl" includes and -(C₃-C₇)cycloalkyl.


The term, "heterocyclic radical", refers to 30 radicals derived from monocyclic or polycyclic, saturated or unsaturated, substituted or unsubstituted heterocyclic nuclei having 5 to 14 ring atoms and containing from 1 to 3 hetero atoms selected from the group consisting of nitrogen, oxygen or sulfur. Typical heterocyclic radicals are

X-12143A

-9-

pyridyl, thienyl, fluorenyl, pyrrolyl, furanyl, thiophenyl,
 pyrazolyl, imidazolyl, phenylimidazolyl, triazolyl,
 isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, indolyl,
 carbazolyl, norharmanyl, azaindolyl, benzofuranyl,
 5 dibenzofuranyl, thianaphtheneyl, dibenzothiophenyl,
 indazolyl, imidazo(1.2-A)pyridinyl, benzotriazolyl,
 anthranilyl, 1,2-benzisoxazolyl, benzoxazolyl,
 benzothiazolyl, purinyl, pyridinyl, dipyridylyl,
 phenylpyridinyl, benzylpyridinyl, pyrimidinyl,
 10 phenylpyrimidinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl,
 phthalazinyl, quinazolinyl, and quinoxalinyl.

The term "carbocyclic radical" refers to radicals derived from a saturated or unsaturated, substituted or unsubstituted 5 to 14 membered organic nucleus whose ring 15 forming atoms (other than hydrogen) are solely carbon atoms. Typical carbocyclic radicals are cycloalkyl, cycloalkenyl, phenyl, naphthyl, norbornanyl, bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenylyl, diphenylethylenyl, phenylcyclohexeyl, acenaphthylenyl, and anthracenyl,
 20 biphenyl, bibenzylyl and related bibenzylyl homologues represented by the formula (bb),



25 where n is an integer from 1 to 8.

The term, "non-interfering substituent", refers to radicals suitable for substitution at positions 1, 2, 3, 7 and/or 8 on the tricyclic nucleus (as depicted in Formula III) and radical(s) suitable for substitution on the
 30 heterocyclic radical and carbocyclic radical as defined above. Illustrative non-interfering radicals are hydrogen, -(C₁-C₁₄)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

X-12143A

-10-

- (C₇-C₁₂)aralkyl, - (C₇-C₁₂)alkaryl, - (C₃-C₈)cycloalkyl,
- (C₃-C₈)cycloalkenyl, phenyl, toluyl, xylenyl, biphenyl,
- (C₁-C₆)alkoxy, - (C₂-C₆)alkenyloxy, - (C₂-C₆)alkynyloxy,
- (C₁-C₁₂)alkoxyalkyl, - (C₁-C₁₂)alkoxyalkyloxy,
- 5 - (C₁-C₁₂)alkylcarbonyl, - (C₁-C₁₂)alkylcarbonylamino,
- (C₁-C₁₂)alkoxyamino, - (C₁-C₁₂)alkoxyaminocarbonyl,
- (C₁-C₁₂)alkylamino, - (C₁-C₆)alkylthio,
- (C₁-C₁₂)alkylthiocarbonyl, - (C₁-C₆)alkylsulfinyl,
- (C₁-C₆)alkylsulfonyl, - (C₁-C₆)haloalkoxy,
- 10 - (C₁-C₆)haloalkylsulfonyl, - (C₁-C₆)haloalkyl,
- (C₁-C₆)hydroxyalkyl, - (CH₂)_nCN, - (CH₂)_nNR⁹R¹⁰,
- C(O)O(C₁-C₆alkyl), - (CH₂)_nO(C₁-C₆ alkyl), benzyloxy,
- phenoxy, phenylthio; - (CONHSO₂)R¹⁵, where R¹⁵ is - (C₁-C₆)alkyl; - CF₃, naphthyl or - (CH₂)_sphenyl where s is 0-5;
- 15 - CHO, - CF₃, - OCF₃, pyridyl, amino, amidino, halo, carbamyl, carboxyl, carbalkoxy, - (CH₂)_nCO₂H, cyano, cyanoguanidinyl, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, nitro, phosphono, - SO₃H, thioacetal, thiocarbonyl, furyl, thiophenyl - COR⁹, - CONR⁹R¹⁰, - NR⁹R¹⁰, -
- 20 NHCOR⁹, - SO₂R⁹, - OR⁹, - SR⁹, CH₂SO₂R⁹, tetrazolyl or tetrazolyl substituted with - (C₁-C₆)alkyl, phenyl or - (C₁-C₄)alkylphenyl, - (CH₂)_nOSi(C₁-C₆)alkyl and (C₁-C₆)alkylcarbonyl; where n is from 1 to 8 and R⁹ and R¹⁰ are independently hydrogen, - CF₃, phenyl, - (C₁-C₄)alkyl, - (C₁-C₄)alkylphenyl or - phenyl(C₁-C₄)alkyl
- 25







The term, "acidic group" means an organic group which when attached to a tricyclic nucleus, through suitable linking atoms (hereinafter defined as the "acid linker"), acts as a proton donor capable of hydrogen bonding. Illustrative of an acidic group are the following:

X-12143A

-11-



 $-\text{CO}_2\text{H}$, $-\text{5-tetrazolyl}$, $-\text{SO}_3\text{H}$,

5



X-12143A

-12-



where n is 1 to 8, R89 is a metal or -(C₁-C₁₀)alkyl, and R99 is hydrogen or -(C₁-C₁₀)alkyl.

The words, "acid linker" refer to a divalent linking group symbolized as, -(L_a)-, which has the function of joining the 5 or 6 position of the tricyclic nucleus to an acidic group in the general relationship:

(tricyclic nucleus) -(L_a)- Acidic Group


10

The words, "acid linker length", refer to the number of atoms (excluding hydrogen) in the shortest chain of the linking group -(L_a)- that connects the 5 or 6 position of the tricyclic nucleus with the acidic group.


15 The presence of a carbocyclic ring in -(L_a)- counts as the number of atoms approximately equivalent to the calculated diameter of the carbocyclic ring. Thus, a benzene or cyclohexane ring in the acid linker counts as 2 atoms in calculating the length of -(L_a)-. Illustrative acid linker
20 groups are;

X-12143A


-13-




(a)



(b)



(c)





(d)

5 where t is 1 to 5, Q is selected from the group $-(\text{CH}_2)-$,
 -O-, -NH-, and -S-, and R₈₄ and R₈₅ are each independently
 selected from hydrogen, -(C₁-C₁₀)alkyl, aryl, -(C₁-
 C₁₀)alkaryl, -(C₁-C₁₀)aralkyl, carboxy, carbalkoxy, and
 halo, when t is one (1), groups (a), (b), (c) and (d) have
 10 acid linker lengths of 3, 3, 2, and 2, respectively.

The skilled artisan will appreciate that the position of the double bond in the center 5-membered ring depends on the position of the nitrogen atom as depicted below.

X-12143A

-14-



The salts of the above tricyclics are an additional aspect of the invention. In those instances where the compounds of the invention possess acidic functional groups various salts may be formed which are more water soluble and physiologically suitable than the parent compound. Representative pharmaceutically acceptable salts include but are not limited to the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion exchange resin.

Included within the definition of pharmaceutically acceptable salts are the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Phar. Sci., 66: 1-19 (1977)).

Compounds of the invention may have chiral centers and exist in optically active forms. R- and S-isomers and racemic mixtures are contemplated by this invention. A particular stereoisomer may be prepared by known methods using stereospecific reactions with starting materials containing asymmetric centers already resolved

X-12143A

-15-

or, alternatively, by subsequent resolution of mixtures of stereoisomers using known methods.

Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives, such as, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine. Simple aliphatic esters (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl) or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs. Other preferred esters include morpholinoethoxy, diethylglycolamide and diethylaminocarbonylmethoxy. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters.

The term "acid protecting group" is used herein as it is frequently used in synthetic organic chemistry, to refer to a group which will prevent an acid group from participating in a reaction carried out on some other functional group in the molecule, but which can be removed when it is desired to do so. Such groups are discussed by T. W. Greene in chapter 5 of Protective Groups in Organic Synthesis, John Wiley and Sons, New York, 1981, incorporated herein by reference in its entirety.

X-12143A

-16-


Examples of acid protecting groups include ester or amide derivatives of the acid group, such as, methyl, methoxymethyl, methyl-thiomethyl, tetrahydropyranyl, methoxyethoxymethyl, benzyloxymethyl, phenyl, aryl, ethyl,
5 2,2,2-trichloroethyl, 2-methylthioethyl, t-butyl, cyclopentyl, triphenylmethyl, diphenylmethyl, benzyl, trimethylsilyl, N,N-dimethyl, pyrrolidinyl, piperidinyl, or o-nitroanilide. A preferred acid-protecting group is methyl.

10

The compounds of formula I where Z is cyclohexene are prepared according to the following reaction Schemes I(a)-(b) and II.

X-12143A

-17-

Scheme I (a)

Wherein;

R^1 is $-\text{NH}_2$, $\text{R}^3(a)$ is H , $-\text{O}(\text{C}_1\text{-}\text{C}_4)\text{alkyl}$, halo, $-(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, phenyl, $-(\text{C}_1\text{-}\text{C}_4)\text{alkylphenyl}$; phenyl substituted with $-(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, halo, or $-\text{CF}_3$; $-\text{CH}_2\text{OSi}(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, furyl, thiophenyl, $-(\text{C}_1\text{-}\text{C}_6)\text{hydroxyalkyl}$, $-(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, $-(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}(\text{C}_1\text{-}\text{C}_6)\text{alkenyl}$; or $-(\text{CH}_2)_n\text{R}^8$ where R^8 is H , $-\text{CONH}_2$, $-\text{NR}^9\text{R}^{10}$, $-\text{CN}$ or phenyl where R^9 and R^{10}

X-12143A

-18-

are independently hydrogen, -CF₃, phenyl, -(C₁-C₄)alkyl, -(C₁-C₄)alkylphenyl or -phenyl(C₁-C₄)alkyl and n is 1 to 8;

when R¹ is -NHNH₂, R^{3(a)} is H, -O(C₁-C₄)alkyl, halo, -(C₁-C₆)alkyl, phenyl, -(C₁-C₄)alkylphenyl; phenyl substituted with -(C₁-C₆)alkyl, halo or -CF₃; -CH₂OSi(C₁-C₆)alkyl, furyl, thiophenyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)alkoxy(C₁-C₆)alkyl, -(C₁-C₆)alkoxy(C₁-C₆)alkenyl; or -(CH₂)_nR⁸ where R⁸ is H, -NR⁹R¹⁰, -CN or phenyl where R⁹ and R¹⁰ are independently hydrogen, -CF₃, phenyl, -(C₁-C₄)alkyl, -(C₁-C₄)alkylphenyl or -phenyl(C₁-C₄)alkyl and n is 1 to 8;

R^{2(a)} is -OCH₃ or -OH.

An appropriately substituted nitrobenzene (1) can be reduced to the aniline (2) by treatment with a reducing agent, such as hydrogen in the presence of Pd/C, preferably at room temperature.

Compound (2) is N-alkylated at temperatures of from about 0 to 20°C using an alkylating agent such as an appropriately substituted aldehyde and sodium cyanoborohydride to form (3). Alternately, an appropriately substituted benzyl halide may be used for the first alkylation step. The resulting intermediate is further N-alkylated by treatment with 2-carbethoxy-6-bromocyclohexanone, preferably at temperatures of about 80°C to yield (4) or by treatment with potassium hexamethyldisilazide and the bromoketoester.


The product (4) is cyclized to the tetrahydrocarbazole (5) by refluxing with ZnCl₂ in benzene for from about 1 to 2 days, preferably at 80°C. (Ref 1). Compound (5) is converted to the hydrazide (6) by treatment with hydrazine at temperatures of about 100°C, or to the amide (7) by reacting with methylchloroaluminum

X-12143A

-19-

amide in benzene. (Ref 2) Alternatively, (7) may be produced by treatment of (6) with Raney nickel active catalyst.

It will be readily appreciated that when $R^3(a)$ is:



conversion to the amide will also be achieved in this procedure.

Compounds (6) and (7) may be dealkylated, preferably at 0°C to room temperature, with a dealkylating agent, such as boron tribromide or sodium thioethoxide, to give compound (7) where R^{2(a)} is -OH, which may then be further converted to compound (9), by realkylating with a base, such as sodium hydride, and an alkylating agent, such as Br(CH₂)_mR⁵, where R⁵ is the carboxylate or phosphonic diester or nitrile as defined above.

Conversion of R² to the carboxylic acid may be accomplished by treatment with an aqueous base. When R² is nitrile, conversion to the tetrazole may be achieved by reacting with tri-butyl tin azide or conversion to the carboxamide may be achieved by reacting with basic hydrogen peroxide. When R² is the phosphonic diester, conversion to the acid may be achieved by reacting with a dealkylating agent such as trimethylsilyl bromide. The monoester may be accomplished by reacting the diester with an aqueous base.

When R² and R³ are both methoxy, selective demethylation can be achieved by treating with sodium ethanethiolate in dimethylformamide at 100°C.

30 Ref 1 Julia, M.; Lenzi, J. Preparation d'acides tetrahydro-1,2,3,4-carbazole-1 ou -4.

Bull. Soc. Chim. France, 1962, 2262-2263.


X-12143A

-20-

Ref 2 Levin, J.I.; Turos, E.; Weinreb, S.M. An alternative procedure for the aluminum-mediated conversion of esters to amides. *Syn. Comm.*, 1982, 12, 989-993.

5

An alternative synthesis of intermediate (5) is shown in Scheme I(b), as follows.

Scheme I(b)

10 where PG is a protecting group;


R^{3a} is as defined in Scheme 1, above.

The aniline (2) is N-alkylated with 2-carbethoxy-6-bromocyclohexanone in dimethyl formamide in the presence
 15 of sodium bicarbonate for 8-24 hours at 50°C. Preferred
 protecting groups include methyl, carbonate, and silyl
 groups, such as t-butyldimethylsilyl. The reaction product
 (4') is cyclized to (5') using the ZnCl₂ in benzene
 conditions described in Scheme I(a), above. N-alkylation of
 20 (5') to yield (5) is accomplished by treatment with sodium

X-12143A

-21-

hydride and the appropriate alkyl halide in dimethylformamide at room temperature for 4-8 hours.

Scheme II

5

$\text{R}^3(a)$ is as defined in Scheme I.

As discussed in Scheme I above, carbazole (5) is hydrolyzed to the carboxylic acid (10) by treatment with an aqueous base, preferably at room temperature to about 100°C. The intermediate is then converted to an acid chloride utilizing, for example, oxalyl chloride and dimethylformamide, and then further reacted with a lithium

X-12143A

-22-

salt of (S) or (R)-4-alkyl-2-oxazolidine at a temperature of about -75°C, to give (11a) and (11b), which are separable by chromatography.


The diastereomers are converted to the corresponding enantiomeric benzyl esters (12) by brief treatment at temperatures of about 0°C to room temperature with lithium benzyl oxide. (Ref 3) The esters (12) are then converted to (7) preferably by treatment with methylchloroaluminum amide (Ref 2, above) or, alternately, by hydrogenation using, for example, hydrogen and palladium on carbon, as described above, to make the acid and then reacting with an acyl azide, such as diphenylphosphoryl azide followed by treatment with ammonia. Using the procedure described above in Scheme I, compound (9a) or (9b) may be accomplished.

Ref 3 Evans, D.A.; Ennis, M.D.; Mathre, D.J. Asymmetric alkylation reactions of chiral imide enolates. A practical approach to the enantioselective synthesis of alpha-substituted carboxylic acid derivatives. *J. Am. Chem. Soc.*, 1982, 104, 1737-1738.

Compounds of formula I where Z is phenyl can be prepared as follows in Schemes III(a) - (g), below.

25

Scheme III (a)



X-12143A

-23-

A 1,2,3,4-tetrahydrocarbazole-4-carboxamide or 4-carboxhydrazide (13) is dehydrogenated by refluxing in a solvent such as carbitol in the presence of Pd/C to produce the carbazole-4-carboxamide. Alternately,

- 5 treatment of (13) with DDQ in an appropriate solvent such as dioxane yields carbozole (14).

Depending on the substituent pattern oxidation as described above may result in de-alkylation of the nitrogen. For example when R³ is substituted at the 8-
10 position with methyl, oxidation results in dealkylation of the nitrogen which may be realkylated by treatment with sodium hydride and the appropriate alkyl halide as described in Scheme I(a) above to prepare the desired product (14).


15 The intermediates and final products may be isolated and purified by conventional techniques, for example by concentration of the solvents, followed by washing of the residue with water, then purification by conventional techniques, such as chromatography or
20 recrystallization.

It will be readily appreciated by the skilled artisan that the starting materials are either commercially available or can be readily prepared by known techniques from commercially available starting materials.
25 All other reactants used to prepare the compounds in the instant invention are commercially available.

X-12143A

-24-

Scheme III(b)



X-12143A

-25-

5 Benzoic acid derivative(16) where X is preferably chlorine, bromine or iodine and the protecting group is preferably -CH₃, are reduced to the corresponding aniline (25) with a reducing agent, such as stannous chloride in the presence of acid under the general conditions of Sakamoto et al, Chem Pharm. Bull. 35 (5), 1823-1828 (1987).

10 Alternatively, reduction with sodium dithionite in the presence of a base, such as sodium carbonate in a noninterferring solvent, such as water, ethanol, and/or tetrahydrofuran affords starting material (16).

15 Alternatively, reduction by hydrogenation over a sulfided platinum catalyst supported on carbon with hydrogen at 1 to 60 atmospheres in a noninterfering solvent, preferably ethyl acetate, to form a starting material (16).

The reactions are conducted at temperatures from about 0 to 100°C. preferably at ambient temperature, and are substantially complete in about 1 to 48 hours depending on conditions.

20 The aniline (25) and dione (15) are condensed under dehydrating conditions, for example, using the general procedure of Iida, et al., (Ref 5), with or without a noninterfering solvent, such as toluene, benzene, or methylene chloride, under dehydrating conditions at a temperature about 10 to 150°C. The water formed in the process can be removed by distillation, azeotropic removal via a Dean-Stark apparatus, or the addition of a drying agent, such as molecular sieves, magnesium sulfate, calcium carbonate, sodium sulfate, and the like.

25 The process can be performed with or without a catalytic amount of an acid, such a p-toluenesulfonic acid or methanesulfonic acid. Other examples of suitable catalysts include hydrochloric acid, phenylsulfonic acid, calcium chloride, and acetic acid.

X-12143A

-26-

Examples of other suitable solvents include tetrahydrofuran, ethyl acetate, methanol, ethanol, 1,1,2,2-tetrachloroethane, chlorobenzene, bromobenzene, xylenes, and carbotetrachloride.

5 The condensation of the instant process is preferably carried out neat, at a temperature about 100 to 150°C with the resultant water removed by distillation via a stream of inert gas, such as, nitrogen or argon.

10 The reaction is substantially complete in about 30 minutes to 24 hours.

15 Intermediate (26) may then be readily cyclized in the presence of a palladium catalyst, such as Pd(OAc)₂ or Pd(PPh₃)₄, and the like, a phosphine, preferably a trialkyl- or triarylphosphine, such as triphenylphosphine, tri-o-tolylphosphine, or tricyclohexylphosphine, and the like, a base, such as, sodium bicarbonate, triethylamine, or diisopropylethylamine, in a noninterfering solvent, such as, acetonitrile, triethylamine, or toluene at a temperature about 25 to 200°C to form (19).

20 Examples of other suitable solvents include tetrahydrofuran, benzene, dimethylsulfoxide, or dimethylformamide.

25 Examples of other suitable palladium catalysts include Pd(PPh₃)Cl₂, Pd(OCOCF₃)₂, [(CH₃C₆H₄)₃P]₂PdCl₂, [(CH₃CH₂)₃P]₂PdCl₂, [(C₆H₁₁)₃P]₂PdCl₂, and [(C₆H₅)₃P]₂PdBr₂.

30 Examples of other suitable phosphines include triisopropylphosphine, triethylphosphine, tricyclopentylphosphine, 1,2-bis(diphenylphosphino)ethane, 1,3-bis(diphenylphosphino)propane, and 1,4-bis(diphenylphosphino)butane.

Examples of other suitable bases include tripropylamine, 2,2,6,6-tetramethylpiperidine, 1,5-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-

X-12143A

-27-

diazabicyclo[4.3.0]non-5-ene, (DBN) sodium carbonate, potassium carbonate, and potassium bicarbonate.

The cyclization of the instant process is preferably carried out with palladium(II)acetate as catalyst
5 in the presence of either triphenylphosphine, tri-o-tolylphosphine, 1,3-bis(diphenylphosphino)propane, or tricyclohexylphosphine in acetonitrile as solvent and triethylamine as base at a temperature about 50 to 150°C.
The reaction is substantially complete in about 1 hour to 14
10 days.

Alternatively, a preferred process for cyclization consists of the reaction of intermediate (26) with a palladacycle catalyst such as *trans*-di(μ -acetato)-bis[o-(di-o-tolylphosphino)benzyl]dipalladium (II) in a solvent such
15 as dimethylacetamide (DMAC) at 120-140°C in the presence of a base such as sodium acetate.

Intermediate (19) may be alkylated with an alkylating agent XCH₂R₄, where X is halo in the presence of a base to form (20). Suitable bases include potassium
20 carbonate, sodium carbonate, lithium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, potassium hydroxide, sodium hydroxide, sodium hydride, potassium hydride, lithium hydride, and Triton B (N-benzyltrimethylammonium hydroxide).

25 The reaction may or may not be carried out in the presence of a crown ether. Potassium carbonate and Triton B are preferred. The amount of alkylating agent is not critical, however, the reaction is best accomplished using an excess of alkyl halide relative to the starting material.

30 A catalytic amount of an iodide, such as sodium iodide or lithium iodide may or may not be added to the reaction mixture. The reaction is preferably carried out in an organic solvent, such as, acetone, dimethylformamide, dimethylsulfoxide, or acetonitrile. Other suitable solvents

X-12143A

-28-

include tetrahydrofuran, methyl ethyl ketone, and t-butyl methyl ether.

The reaction is conducted at temperatures from about -10 to 100°C. preferably at ambient temperature, and 5 is substantially complete in about 1 to 48 hours depending on conditions. Optionally, a phase transfer reagent such as tetrabutylammonium bromide or tetrabutylammonium chloride may be employed.

Intermediate (20) may be dehydrogenated by 10 oxidation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in a noninterfering solvent to form (21).

Suitable solvents include methylene chloride, chloroform, carbon tetrachloride, diethyl ether, methyl ethyl ketone, and t-butyl methyl ether. Toluene, benzene, 15 dioxane, and tetrahydrofuran are preferred solvents. The reaction is carried out at a temperature about 0 to 120 °C. Temperatures from 50 to 120°C are preferred. The reaction is substantially complete in about 1 to 48 hours depending on conditions.

20 Intermediate (21) may be aminated with ammonia in the presence of a noninterfering solvent to form a(22). Ammonia may be in the form of ammonia gas or an ammonium salt, such as ammonium hydroxide, ammonium acetate, ammonium trifluoroacetate, ammonium chloride, and the like. Suitable 25 solvents include ethanol, methanol, propanol, butanol, tetrahydrofuran, dioxane, and water. A mixture of concentrated aqueous ammonium hydroxide and tetrahydrofuran or methanol is preferred for the instant process. The reaction is carried out at a temperature about 20 to 100°C. 30 Temperatures from 50 to 60°C are preferred. The reaction is substantially complete in about 1 to 48 hours depending on conditions.

Alkylation of (22) is achieved by treatment with an alkylating agent of the formula XCH_2R^9 where X is halo

X-12143A

-29-

and R⁷⁰ is -CO₂R⁷¹, -SO₃R⁷¹, -P(O)(OR⁷¹)₂, or -P(O)(OR⁷¹)H, where R⁷¹ is an acid protecting group or a prodrug function, in the presence of a base in a noninterfering solvent to form (23). Methyl bromoacetate and t-butyl bromoacetate are the
5 preferred alkylating agents.

Suitable bases include potassium carbonate, sodium carbonate, lithium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, potassium hydroxide, sodium hydroxide, sodium hydride, potassium hydride, lithium hydride, and Triton B (N-benzyltrimethylammonium hydroxide).
10 The reaction may or may not be carried out in the presence of a crown ether. Cesium carbonate and Triton B are preferred.

The amount of alkylating agent is not critical,
15 however, the reaction is best accomplished using an excess of alkyl halide relative to the starting material. The reaction is preferably carried out in an organic solvent, such as, acetone, dimethylformamide, dimethylsulfoxide, or acetonitrile. Other suitable solvents include
20 tetrahydrofuran, methyl ethyl ketone, and t-butyl methyl ether.

The reaction is conducted at temperatures from about -10 to 100°C. preferably at ambient temperature, and is substantially complete in about 1 to 48 hours depending
25 on conditions. Optionally, a phase transfer reagent such as tetrabutylammonium bromide or tetrabutylammonium chloride may be employed.

Intermediate (23) may be optionally hydrolyzed with a base or acid to form desired product (24) and
30 optionally salified.

Hydrolysis of (23) is achieved using a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, aqueous potassium carbonate, aqueous sodium carbonate, aqueous lithium carbonate, aqueous potassium bicarbonate,

X-12143A

-30-

aqueous sodium bicarbonate, aqueous lithium bicarbonate, preferably sodium hydroxide and a lower alcohol solvent, such as, methanol, ethanol, isopropanol, and the like. Other suitable solvents include acetone, tetrahydrofuran, and
5 dioxane.

Alternatively, the acid protecting group may be removed by organic and inorganic acids, such as trifluoroacetic acid and hydrochloric acid with or without a noninterferring solvent. Suitable solvents include methylene
10 chloride, tetrahydrofuran, dioxane, and acetone. The t-butyl esters are preferably removed by neat trifluoroacetic acid.

The reaction is conducted at temperatures from about -10 to 100°C. preferably at ambient temperature, and is substantially complete in about 1 to 48 hours depending
15 on conditions.


The starting material (16) is prepared by esterifying compound (15) with a alkyl halide = XPG; where X is halo and PG is an acid protecting group, in the presence of a base, preferably potassium carbonate or sodium
20 carbonate, in a noninterferring solvent, preferably dimethylformamide or dimethylsulfoxide. The preferred alkyl halide is methyl iodide. The reaction is conducted at temperatures from about 0 to 100°C. preferably at ambient temperature, and is substantially complete in about 1 to 48
25 hours depending on conditions.

Alternatively the starting material (16) may be prepared by condensation with an alcohol HOPG, where PG is an acid protecting group, in the presence of a dehydrating catalyst such as, dicyclohexylcarbodiimide (DCC) or carbonyl
30 diimidazole.

In addition, U.S. Patent No. 4,885,338 and Jpn. Kokai Tokkyo Koho 05286912, Nov 1993 Hesei teach a method for preparing 2-fluoro-5-methoxyaniline derivatives.

X-12143A

-31-

Scheme III(c)

R is as defined in Scheme III(b),

 $\text{R}^{3(a)}$ is as defined in Scheme I(a), above; and

5 X is halo.

Benzoic acid derivatives (16) ($\text{X} = \text{Cl}, \text{Br}$, or I) and boronic acid derivative (27) (either commercially available or readily prepared by known techniques from 10 commercially available starting materials) are condensed under the general procedure of Miyaura, et al., (Ref 8a) or Trecourt, et al., (Ref 8b) in the presence of a palladium catalyst, such as $\text{Pd}(\text{Ph}_3\text{P})_4$, a base, such as

X-12143A

-32-

sodium bicarbonate, in an inert solvent, such as THF, toluene or ethanol, to afford compound (28).

Compound (28) is converted to the carbazole product (29) by treatment with a trialkyl or triaryl phosphite or phosphine, such as, triethylphosphite or triphenyl phosphine, according to the general procedure of Cadogan, et al. (Ref 6).

Compound (29) is N-alkylated with an appropriately substituted alkyl or aryl halide XCH_2R^4 in the presence of a base, such as sodium hydride or potassium carbonate, in a noninterfering solvent, such as toluene, dimethylformamide, or dimethylsulfoxide to afford carbazole (30).

Compound (30) is converted to the corresponding amide (22) by treatment with boron tribromide or sodium thioethoxide, followed by ammonia or an ammonium salt, such as ammonium acetate, in an inert solvent, such as water or alcohol, or with methylchloroaluminum amide in an inert solvent, such as toluene, at a temperature between 0 to 110°C.


When $R^3(a)$ is substituted at the 8-position with chloro, de-alkylation of (30) with boron tribromide results in de-benzylation of the nitrogen as described above. Alkylation may be readily accomplished in a two step process. First, an O-alkylation by treatment with a haloalkyl acetate such as methyl bromo acetate using sodium hydride in tetrahydrofuran, followed by N-alkylation using for example a base such as sodium hydride and an appropriately substituted alkyl or aryl halide in dimethoxy formamide. Compound (22) can be converted to product carbazole product (24) as described previously in Scheme III(b) above.

Conversion to the desired prodrug may be accomplished by techniques known to the skilled artisan,

X-12143A

-33-

such as for example, by treatment with a primary or secondary halide to make an ester prodrug.

Scheme III(d)

5 Alternatively, reduction of the nitro group of compound (28) with a reducing agent, such as hydrogen in the presence of palladium on carbon, in a noninterfering solvent, such as ethanol, at 1 to 60 atmospheres, at a temperature of 0 to 60°C affords the corresponding aniline
10 10 (32). Compound (32) is converted to the carbazole (29) according to the general procedure described by Trecourt, et al. (Ref 8b). The aniline is treated with sulfuric acid and sodium nitrite, followed by sodium azide to form an intermediate azide which is cyclized to carbazole (29)
15 15 by heating in an inert solvent, such as toluene. Compound (29) is converted to carbazole product (24) as described previously in Schemes III(b) and III(c).


References:

- 20 8) a. N. Miyaura, et al., *Synth. Commun.* 11, 513 (1981)
 b. F. Trecourt, et al., *Tetrahedron*, 51, 11743 (1995)
- 6) J. Cadogan et al., *J. Chem. Soc.*, 4831 (1965)

X-12143A

- 34 -

Scheme III(e)



In an aprotic solvent, preferably


- 5 tetrahydrofuran, reduction of (40) is achieved using a
reducing agent such as aluminum trihydride. Preferably,
the reaction is conducted under inert atmosphere such as
nitrogen, at room temperature.

Sulfonylation may be achieved with an

- 10 appropriate acylating agent in the presence of an acid scavenger such as triethyl amine.

X-12143A


-35-

Scheme III (f)

In a two-step, one-pot process, intermediate (50), prepared as described in Scheme I(a) above, is first activated with an activating agent such as carbonyl diimidazole. The reaction is preferably run in an aprotic polar or non-polar solvent such as tetrahydrofuran. Acylation with the activated intermediate is accomplished by reacting with $\text{H}_2\text{NSO}_2\text{R}^{15}$ in the presence of a base, preferably diazabicycloundecene.

X-12143A

-36-

Scheme III(g)

PG is an acid protecting group;

R²² is (C₁-C₆)alkoxy (C₁-C₆)alkyl is (C₁-C₆)alkoxy (C₁-C₆)alkenyl

- 5 Starting material (20) is O-alkylated with an alkyl halide or alkenyl halide, using a base such as NaH, in an aprotic polar solvent preferably anhydrous DMF, at ambient temperature under a nitrogen atmosphere. The process of aromatization from a cyclohexenone
- 10 functionality to a phenol functionality can be performed by treating the tetrahydrocabazole intermediate (60) with a base such as NaH in the presence of methyl benzenesulfinate in an anhydrous solvent, such as 1,4-

X-12143A

-37-

- dioxane or DMF, to form the ketosulfoxide derivative. Upon heating at about 100°C for 1-2 hours, the ketosulfoxide derivative (60) is converted to the phenol derivative (61). Conversion of the ester (61) to the 5 amide (62) can be achieved by treating a solution of (61) in an aprotic polar solvent such as tetrahydrofuran with ammonia gas. Phenolic O-alkylation of (62) with, for example, methyl bromoacetate can be carried out in anhydrous DMF at ambient temperature using Cs₂CO₃ or K₂CO₃ 10 as a base to form (63). Desired product (64) can be derived from the basic hydrolysis of ester (63) using LiOH or NaOH as a base in an H₂O/CH₃OH/THF solution at 50°C for 1-2 hours.
- When R²² is -(C₁-C₆)alkoxy(C₁-C₆)alkenyl, 15 hydrogenation of the double bond can be performed by treating (63) in THF using PtO₂ as a catalysis under a hydrogen atmosphere. Desired product can then be derived as described above in Scheme III(g) from the basic hydrolysis of ester (63) using LiOH or NaOH as a base in an 20 H₂O/CH₃OH/THF solution at 50°C for 1-2 hours.

The following list of abbreviations are used in the Examples and Preparations.

	HCl	= hydrochloric acid
25	EtOAc	= ethyl acetate
	DMF	= dimethyl formamide
	THF	= tetrahydrofuran
	Et ₂ O	= diethyl ether
	H ₂ O	= water
30	NaOH	= sodium hydroxide
	EtOH	= ethanol
	Na ₂ SO ₄	= sodium sulfate
	NaHCO ₃	= sodium bicarbonate
	celite	= diatomaceous earth

X-12143A

-38-


	CH ₂ Cl ₂	= methylene chloride
	H ₂ SO ₄	= sulfuric acid
	MeOH	= methanol
	Rh/Al ₂ O ₃	= rhodium on alumina
5	DDQ	= 2,3-dichloro-5,6-dicyano-1,4-benzo- quinone
	TLC	= thin layer chromatography
	NaH	= sodium hydride
	NH ₄ OH	= ammonium hydroxide
10	LiOH	= lithium hydroxide
	NH ₃	= ammonia
	Cs ₂ CO ₃	= cesium carbonate
	NH ₄ OAc	= ammonium acetate

The following preparations of intermediates and
15 examples of final products further illustrate the preparation
of the compounds of this invention. The examples are
illustrative only and are not intended to limit the scope of
the invention in any way.

20

Preparation 1

Preparation of 5-Carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-
one from 2-bromo-3-nitrobenzoic acid



25 a) Methyl 2-bromo-3-nitrobenzoate

A solution of 2-bromo-3-nitrobenzoic acid (28.4 g, 115.0 mM), iodomethane (18.0 g, 127 mM), and potassium carbonate (19.0 g, 137.4 mM) in 100 mL DMF was stirred at

X-12143A

-39-

room temperature for 72 hours. The mixture was poured into 1.5 liters of H₂O. The resultant precipitate was collected by filtration and dried *in vacuo* to afford 28.79 g (96%) of methyl 2-bromo-3-nitrobenzoate as a white solid. ¹H NMR

5 (DMSO-d₆) δ 8.3 (dd, 1H, J=1 and 8 Hz), 7.9 (dd, 1H, J=1 and 8 Hz), 7.7 (t, 1H, J=8 Hz), and 3.9 (s, 3H). IR (KBr, cm⁻¹) 2950, 1738, 1541, 1435, 1364, 1298, and 1142. MS (FD) m/e 259, 261.

Elemental Analyses for C₈H₆NO₄Br:

10 Calculated: C, 36.95; H, 2.33; N, 5.39.
Found: C, 37.14; H, 2.37; N, 5.45.

b) Methyl 2-bromo-3-aminobenzoate

Hydrogen gas was passed through a solution of methyl 2-bromo-3-nitrobenzoate (0.20 g, 0.77 mM) and 0.1 g of 3% sulfided platinum on carbon in 25 mL ethyl acetate for 24 hours at room temperature. The catalyst was removed by filtration through celite. Concentration of the filtrate afforded 0.175 g (99%) of methyl 2-bromo-3-aminobenzoate as a yellow oil. ¹H NMR (CDCl₃) δ 7.15 (t, 1H, J=8 Hz), 7.1 (dd, 1H, J=1 and 8 Hz), 6.8 (dd, 1H, J=1 and 8 Hz), and 3.95 (s, 3H). IR (CHCl₃, cm⁻¹) 3550, 3380, 2980, 2900, 1729, 1613, 1465, 1451, 1434, 1324, 1266, and 1025. MS (FD) m/e 230, 232.

25 Elemental Analyses for C₈H₈NO₂Br:

Calculated: C, 41.77; H, 3.51; N, 6.09.
Found: C, 42.01; H, 3.29; N, 6.00.

b)' In an alternate procedure, Methyl 2-bromo-3-aminobenzoate may be prepared as follows:

A solution of stannous chloride (15.0 g, 76.1 mM) in 30 mL of concentrated hydrochloric acid was slowly added to a solution of methyl 2-bromo-3-nitrobenzoate (4.0 g, 15.4 mM) in 90 mL ethanol at 15-30 °C over 1 hour. The mixture was

X-12143A

-40-

then heated at 50-60 °C for 15 minutes. The mixture was cooled to room temperature and made alkaline by slow addition of solid sodium hydroxide maintaining a temperature of 30-35 °C. The resultant mixture was extracted three

5 times with chloroform. The extracts were washed with brine, dried over sodium sulfate, filtered and concentrated to afford 3.51 g (99%) of methyl 2-bromo-3-aminobenzoate as a yellow oil, identical in all respects to the material derived via catalytic hydrogenation described above.

10

c) 3-(3-Carbomethoxy-2-bromoanilino)cyclohex-2-en-1-one

A mixture of methyl 2-bromo-3-aminobenzoate (13.2 g, 60.0 mM) and 1,3-cyclohexanedione (8.4 g, 75 mM) was heated at 125 °C under a stream of nitrogen for 4 h. The resultant solid was purified by HPLC on silica gel (elution with methylene chloride/ethyl acetate) to afford 17.2 g (88%) of 3-(3-carbomethoxy-2-bromoanilino)cyclohex-2-en-1-one as a tan foam. ¹H NMR (DMSO-d6) δ 8.75 (s, 1H), 7.6-7.4 (m, 3H), 4.65 (s, 1H), 3.85 (s, 3H), 2.6 (t, 2H, J=6 Hz), 2.15 (t, 2H, J=6 Hz), and 1.9 (m, 2H). IR (CHCl₃, cm⁻¹) 3400, 3004, 2954, 1732, 1607, 1588, 1573, 1513, 1464, 1436, 1412, 1308, 1249, 1177, and 1144. MS (ES) m/e 322, 324, 326.

Elemental Analyses for C₁₄H₁₄NO₃Br:

Calculated: C, 51.85; H, 4.32; N, 4.32.

25

Found: C, 53.60; H, 4.73; N, 4.09.

d) 5-Carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one

A suspension of 3-(3-carbomethoxy-2-bromoanilino)cyclohex-2-en-1-one (15.8 g, 48.8 mM), 30 palladium acetate (1.12 g, 5.0 mM), tri-*o*-tolylphosphine (3.1 g, 10.0 mM), and triethylamine (6.3 g, 62.0 mM) in 120 mL acetonitrile was heated at reflux for 8 hours. The solvent was removed in vacuo. The residue was dissolved in methylene chloride, washed twice with 1 N HCl, twice with

X-12143A


-41-

H_2O , once with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated to afford 17 g of a light brown foam. Purification by HPLC on silica gel (elution with gradient methylene chloride/ethyl acetate) 5 afforded 9.2 g (78%) of the 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one as a yellow solid, identical with the material derived from 3-(3-carbomethoxy-2-chloroanilino)cyclohex-2-en-1-one, described above. ^1H NMR (DMSO-d6) δ 7.5 (d, 1H, $J=8$ Hz), 7.25-7.1 (m, 2H), 5.7 (s, 1H), 3.8 (s, 3H), 2.95 (t, 2H, $J=6$ Hz), 2.4 (t, 2H, $J=6$ Hz), and 2.1 (m, 2H). MS (ES) m/e 242, 244.

10

EXAMPLE 1

15 Preparation of {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt



A. 9-[(Phenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one
 20 A suspension of 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one (300 mg, 1.23 mM), benzyl bromide (210 mg, 1.23 mM), and potassium carbonate (170 mg, 1.23 mM) in 15 mL DMF was stirred at room temperature for 6 hours. The mixture was diluted with 80 mL H_2O and chilled in the refrigerator. The 25 resultant white precipitate was collected by filtration, washed with H_2O , and dried *in vacuo* to afford 325 mg (79%) of the 9-[(phenyl)methyl]-5-carbomethoxy-1,2-

X-12143A

-42-

dihydrocarbazol-4(3H)-one as a white solid. ^1H NMR (DMSO-d₆) δ 7.7 (dd, 1H, J=1 and 8 Hz), 7.45-7.0 (m, 7H), 5.6 (s, 2H), 3.8 (s, 3H), 3.05 (t, 2H, J=6 Hz), 2.5 (t, 2H, J=6 Hz), and 2.2 (m, 2H). IR (KBr, cm⁻¹) 3421, 1726, 1676, 1636, 5 1473, 1450, 1435, 1288, 1122, 764, 745, and 706. MS (ES) m/e 334.

Elemental Analyses for C₂₁H₁₉NO₃:

Calculated: C, 75.68; H, 5.71; N, 4.20.
 Found: C, 70.85; H, 5.53; N, 4.49.

10

B. 9-[(Phenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole
 (a) A solution of the 9-[(phenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (1.5 g, 4.5 mM) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (1.12 g, 5.0 mM) in 25 mL of toluene was stirred between 80-90 °C for 6 h. The mixture was purified directly by column chromatography on silica gel (elution with methylene chloride/ethyl acetate) to afford 420 mg (28%) of the 9-[(phenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a yellow solid. ^1H NMR (DMSO-d₆) δ 10.25 (s, 1H), 7.7 (d, 1H, J=8 Hz), 7.4 (t, 1H, J=8 Hz), 7.4-7.0 (m, 8H), 6.6 (d, 1H, J=8 Hz), 5.6 (s, 2H), and 3.8 (s, 3H). IR (CHCl₃, cm⁻¹) 1723, 1685, 1621, 1597, 1568, 1496, 1453, 1442, 1392, 1286, 1267, 1156, and 1138. MS (ES) m/e 330, 332.

15 25 Elemental Analyses for C₂₁H₁₉NO₃:

Calculated: C, 76.13; H, 5.14; N, 4.23.
 Found: C, 75.90; H, 5.20; N, 4.46.

(b) To a solution of the 9-[(phenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (2.87 g, 8.61 mM) in 29 ml dioxane was added 60% sodium hydride in mineral oil (0.79 g, 19.8 mM). The reaction was stirred 8 minutes, then methyl benzenesulfinate (1.80 ml, 13.8 mM) was added. The reaction was stirred an additional 1.5 h, then diluted with 43 ml

X-12143A

-43-

dioxane and 1.13 ml acetic acid. The mixture was refluxed 1 h, diluted with ethyl acetate, and extracted with sat'd NaHCO₃ two times, then with brine. After drying (NaSO₄), evaporation in vacuo afforded 4.90 g. The mixture was 5 purified by column chromatography on silica gel (elution with toluene/methylene chloride) to afford 2.31 g (81%) of the 9-[(phenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole.
¹H NMR (DMSO-d6) δ 10.25 (s, 1H), 7.7 (d, 1H, J=8 Hz), 7.4 (t, 1H, J=8 Hz), 7.4-7.0 (m, 8H), 6.6 (d, 1H, J=8 Hz), 5.6 10 (s, 2H), and 3.8 (s, 3H). IR (CHCl₃, cm⁻¹) 1723, 1685, 1621, 1597, 1568, 1496, 1453, 1442, 1392, 1286, 1267, 1156, and 1138. MS (ES) m/e 330, 332.

Elemental Analyses for C₂₁H₁₇NO₃:

Calculated: C, 76.13; H, 5.14; N, 4.23.
15 Found: C, 75.90; H, 5.20; N, 4.46.

C. 9-[(Phenyl)methyl]-4-hydroxy-5-carbamoyl carbazole
A solution of the 9-[(phenyl)methyl]-4-hydroxy-5- 20 carbomethoxy carbazole (200 mg, 0.6 mM) in 4 mL MeOH and 40 mL concentrated aqueous ammonium hydroxide was sonicated for 30 h at 40-50 °C. The mixture was diluted with ethyl acetate and acidified to pH 1 with 5 N HCl. The aqueous layer was extracted three times with ethyl acetate. The combined organic extracts were washed with saturated brine, dried 25 over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with gradient methylene chloride/ethyl acetate) to afford 50 mg (26%) of the 9-[(phenyl)methyl]-4-hydroxy-5- carbamoyl carbazole as a white solid. ¹H NMR (DMSO-d6) δ 30 10.5 (s, 1H), 8.8 (br s, 1H), 8.4 (br s, 1H), 7.85 (dd, 1H, J=1 and 8 Hz), 7.5-7.1 (m, 9H), 6.6 (d, 1H, J=8 Hz), and 5.8 (s, 2H). IR (KBr, cm⁻¹) 3428, 3198, 3063, 1631, 1599, 1579, 1562, 1496, 1442, 1330, 1261, 1215, 775, and 697. MS (ES) m/e 315, 317.

X-12143A

-44-

Elemental Analyses for C₂₀H₁₆N₂O₂:

Calculated: C, 75.95; H, 5.06; N, 8.86.

Found: C, 74.88; H, 5.40; N, 7.78.

- 5 D. {9-[(Phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester

40% Methanolic Triton B (0.11 mL, 0.24 mM) was added to a solution of the 9-[(phenyl)methyl]-4-hydroxy-5-carbamoyl carbazole (70 mg, 0.22 mM) in 20 mL DMF at 0 °C. After 15 minutes, methyl bromoacetate (70 mg, 0.44 mM) was added and the resultant mixture stirred at room temperature for 5 h. The mixture was diluted with ethyl acetate, washed with 1 N HCl, H₂O, and saturated brine, dried over magnesium sulfate, filtered, and concentrated. The residue was combined with the crude material derived from a similar run utilizing 45 mg (0.14 mM [0.36 mM total]) of 9-[(phenyl)methyl]-4-hydroxy-5-carbamoyl carbazole. The combined residues were purified by column chromatography on silica gel (elution with ethyl acetate) to afford 76 mg (54%) of the {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester as a white solid. ¹H NMR (DMSO-d6) δ 7.65 (d, 1H, J=8 Hz), 7.5 (br s, 1H), 7.4-7.15 (m, 9H), 7.1 (d, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 5.7 (s, 2H), 4.9 (s, 2H), and 3.75 (s, 3H). IR (KBr, cm⁻¹) 3367, 3200, 1760, 1643, 1579, 1496, 1452, 1427, 1216, 1157, 772, and 716. MS (FD) m/e 388.

Elemental Analyses for C₂₃H₂₀N₂O₄:

Calculated: C, 71.13; H, 5.15; N, 7.22.

Found: C, 70.77; H, 5.49; N, 6.79.

- 30 E. {9-[(Phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt.

A solution of the {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester (10.1 mg, 0.025 mM) and 0.025 mL (0.025 mM) of 1 N NaOH in 3 mL of

X-12143A

-45-

ethanol was stirred for 16 h at 25 °C. The resultant white precipitate was collected by filtration, washed with a small amount of EtOH, then dried *in vacuo* to afford 7.1 mg (70%) of the {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-
5 yl}oxyacetic acid, sodium salt as a white powder. ¹H NMR
(DMSO-d6) δ 7.6 (d, 1H, J=8 Hz), 7.5-7.05 (m, 11H), 6.55 (d,
1H, J=8 Hz), 5.75 (s, 2H), and 4.3 (s, 2H). IR (KBr, cm⁻¹)
3471, 1657, 1615, 1591, 1496, 1453, 1412, 1330, 1272, and
1151. MS (ES) m/e 373, 375, 397. Elemental Analyses for
10 C₂₂H₁₇N₂O₄Na: C, 66.67; H, 4.29; N, 7.07. Found C, 66.75; H,
4.55; N, 6.83.

Example 2

Preparation of [9-benzyl-4-carbamoyl-8-fluoro-1,2,3,4-
15 tetrahydrocarbazol-5-yl]oxyacetic acid

A. Preparation of (2-chloro-4-fluorophenyl)- ethyl carbonate

A solution of 19.16 g of 2-chloro-4-fluorophenol in
20 65.4 ml of 2 N aqueous sodium hydroxide solution was cooled
in an ice bath and treated dropwise with 16.3 ml of ethyl
chloroformate. After stirring at room temperature
overnight, the two-phase reaction mixture was diluted with
100 ml of water and extracted with 300 ml of a 1:1
25 pentane/ether mixture. The extract was washed three times
with 0.02 N sodium hydroxide solution, water and then brine.
After drying and evaporation, 27.63 g (97%) of the subtitle
compound were obtained. NMR (300 MHz, CDCl₃): δ 7.23-7.18
(m, 2H); 7.00 (dt, J=8.4, 2.7, 1H); 4.35 (q, J=7.1, 2H);
30 1.40 (t, J=7.1, 3H).

X-12143A

-46-

B. Preparation of (2-chloro-4-fluoro-5-nitrophenyl)- ethyl carbonate

A solution of 27.63 g of (2-chloro-4-fluorophenyl)- ethyl carbonate in 60 ml of dichloromethane was cooled in an
5 ice bath and treated dropwise with 31.86 g of a 1:2 mixture
of fuming nitric acid (90%) and concentrated sulfuric acid.
The reaction was stirred for 2 hours at room temperature and
then cooled with ice and treated with another 4.5 g of the
same nitrating mixture. The reaction was stirred overnight
10 at room temperature, poured into 200 ml of ice and water, and
extracted twice with dichloromethane. The extracts were
washed with water and then with brine, dried over magnesium
sulfate and concentrated to afford 33.01 g (99%) of the
subtitle compound. mp. 50-51 C

15 Elemental Analyses

Calculated: C 41.01; H 2.68; N 5.31; Cl 13.45
Found: C 41.03; H 2.59; N 5.38; Cl 13.71

C. Preparation of 2-chloro-4-fluoro-5-nitroanisole

20 A solution of 15.0 g of (2-chloro-4-fluoro-5-
nitrophenyl)- ethyl carbonate in 100 ml of dimethyl
formamide was treated with 18.6 g of cesium carbonate, 7.1
ml of iodomethane and 7 ml of methanol and stirred overnight
at room temperature. The reaction mixture was poured into
25 water and extracted twice with ether. The extracts were
washed twice with water and then with brine, dried over
magnesium sulfate and concentrated to afford 11.4g of the
subtitle compound. mp. 69-70°C Ex. 57, C.

Elemental Analyses

30 Calculated: C 40.90; H 2.45; N 6.81; Cl 17.25
Found: C 41.20; H 2.48; N 6.70; Cl 17.44

X-12143A

-47-

D. Preparation of 2-fluoro-5-methoxyaniline

A solution of 5.63 g of 2-chloro-4-fluoro-5-nitroanisole in 90 ml of ethanol and 5 ml of triethylamine was hydrogenated at room temperature under 60 pounds per square inch with 1.0 g of 5% palladium on carbon for four hours. The catalyst was filtered off and the solvent was evaporated. The residue was slurried in chloroform and filtered thorough a plug of silica gel and then evaporated. This residue was chromatographed on silica gel using hexane/chloroform mixtures to afford 2.77 g (72%) of the subtitle compound. mp. 253-254°C. NMR (300 MHz, CDCl₃): δ 6.88 (dd, J=10.6, 8.9, 1H); 6.32 (dd, J=7.4, 3.0, 1H); 6.20 (dt, J=8.9, 3.2, 1H); 3.73 (s, 3H); 3.72 (br, 2H).

15 E. Preparation of N-benzyl-2-fluoro-5-methoxyaniline

This procedure was patterned after that of Tietze and Grote, Chem Ber. 126(12), 2733 (1993). A solution of 2.73 g of 2-fluoro-5-methoxyaniline and 2.67 g of benzaldehyde in 48 ml of methanol was treated with 3.43 g of zinc chloride and then cooled in an ice bath. Sodium cyanoborohydride (1.58 g) was added in small poroom temperature ions over 30 minutes and the reaction was stirred for five hours at room temperature. After evaporation of the solvent, the residue was slurried in 40 ml of 1 N sodium hydroxide solution and then extracted twice with ether. The extracts were washed with water and then with brine, dried over magnesium sulfate and concentrated. The residue was recrystallized from hexane to afford 2.61 g and the mother liquors were chromatographed on silica gel using 20:1 hexane/ether to afford another 1.4 g of the subtitle compound (90%). mp. 56-58°C

X-12143A

-48-

Elemental Analyses

Calculated: C 72.71; H 6.10; N 6.06
Found: C 72.51; H 6.06; N 5.99

5 F. Preparation of ethyl 9-benzyl-5-methoxy-8-fluoro-
1,2,3,4-tetrahydrocarbazole-4-carboxylate

A solution of 0.62 g of N-benzyl-2-fluoro-5-methoxyaniline in 20 ml of dry tetrahydrofuran was cooled in an ice bath and treated with 11.3 ml of 0.5 M potassium 10 bis(trimethylsilyl)amide in toluene. After stirring for 30 minutes, 0.74 g of 2-carboethoxy-6-bromocyclohexanone (Sheehan and Mumaw, JACS, 72, 2127 (1950)) in 4 ml of tetrahydrofuran was added and the reaction was allowed to warm slowly to room temperature over two hours. The 15 reaction was quenched with saturated ammonium chloride solution and extracted twice with ether. The extracts were washed with water and then with brine, dried over magnesium sulfate and concentrated. This residue was chromatographed on silica gel using hexane/ ether mixtures to afford 0.796 g 20 (74%) of N-alkylated intermediate diastereomers. This mixture was refluxed in 20 ml of benzene with 0.99 g of zinc chloride overnight. The solvent was evaporated and the residue was partitioned between 25 ml of 1 N HCl and 25 ml of ethyl acetate and then extracted once more with ethyl 25 acetate. The organic layers were washed with water and then brine, dried over magnesium sulfate and concentrated to afford 0.734 g (96%) of the subtitled compound. ESIMS m/e 382 ($M^{+}+1$)

Elemental Analyses

30 Calculated: C 72.42; H 6.34; N 3.67
Found: C 72.20; H 6.26; N 3.70

X-12143A

-49-

G. Preparation of 9-benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxamide

Ethyl 9-benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxylate (0.722 g) was treated similarly as described in Example 49, Part C and chromatographed on silica gel using 1% methanol in dichloromethane to afford 0.482 g (72%) of the subtitle compound. ESIMS m/e 353 ($M^{+}+1$)

Elemental Analyses

10 Calculated: C 71.57; H 6.01; N 7.95
 Found: C 71.42; H 5.83; N 7.75

H. Preparation of [9-benzyl-4-carbamoyl-8-fluoro-1,2,3,4-tetrahydrocarbazol-5-yl]oxyacetic acid methyl ester

15 9-Benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxamide (0.170 g) was converted similarly as described in Example 49, Part D and chromatographed on silica gel using methanol/ 0-1% in dichloromethane to afford 85 mg (50%) of the subtitle 20 compound. mp. 183-185°C

Elemental Analyses

Calculated: C 67.31; H 5.65; N 6.82
 Found: C 67.58; H 5.48; N 6.95

25 I. Preparation of [9-benzyl-4-carbamoyl-8-fluoro-1,2,3,4-tetrahydrocarbazol-5-yl]oxyacetic acid

[9-Benzyl-4-carbamoyl-8-fluoro-1,2,3,4-tetrahydrocarbazol-5-yl]oxyacetic acid methyl ester (71 mg) was hydrolyzed similarly as described in Example 50, Part D 30 to afford 65 mg of the title compound. ESIMS m/e 397 ($M^{+}+1$), 395 ($M^{+}-1$). NMR (300 MHz, d^6 -DMSO): δ 13.03 (br, 1H); 7.31-7.19 (m, 3H); 6.97 (d, $J=7.4$, 2H); 6.95 (br, 1H);

X-12143A

-50-

6.70 (d, J=3.8, 1H); 6.67 (dd, J=12.4, 3.9, 1H); 6.28 (dd, J=8.5, 2.6, 1H); 5.39 (ABq, 2H); 4.64 (s, 2H); 3.92 (br, 1H); 2.71 (m, 1H); 2.44 (m, 1H); 2.02 (m, 2H); 1.76 (m, 2H).

5

Example 3

Preparation of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid

A. Preparation of 9-benzyl-5-carbamoyl-4-methoxy-1-fluorocarbazole
10

A solution of 0.458 g of 9-benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxamide in 13 ml of dry dioxane under nitrogen was treated with 0.59 g of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and refluxed for one hour. The reaction mixture was cooled and filtered and the precipitate was washed with 15 ml of dioxane. The filtrate and washing were poured into saturated sodium bicarbonate solution and extracted three times with ethyl acetate. The extracts were washed with saturated sodium bicarbonate, with water and then with brine; dried over magnesium sulfate and concentrated. This residue was chromatographed on silica gel using dichloromethane/ 0-2% methanol to afford 0.45 g of subtitle compound. ESIMS m/e 349 (M⁺+1)

Elemental Analyses

25 Calculated: C 72.42; H 4.92; N 8.04
 Found: C 72.35; H 4.81; N 7.88

B. Preparation of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid methyl ester

30 A solution of 0.45 g of 9-benzyl-5-carbamoyl-4-methoxy-1-fluorocarbazole in 25 ml of dichloromethane was cooled in an ice bath treated dropwise with 12 ml of 1.0 M boron

X-12143A

-51-

tribromide solution in dichloromethane. The reaction was allowed to warm to room temperature slowly over 2 hours and then quenched by pouring into ice and then adding 50 ml of 1 N HCl. The mixture was extracted with dichloromethane
5 (3x200 ml) and the extracts were dried over magnesium sulfate and concentrated to afford 0.35 g (78%) of the demethylated intermediate. This intermediate (0.215 g) was alkylated and purified similarly to Example GH1, Part D to afford 0.166 g (64%) of the subtitle compound. mp. 190-
10 191°C

Elemental Analyses

Calculated: C 67.97; H 4.71; N 6.89
Found: C 67.81; H 4.94; N 6.96

15 C. Preparation of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid

[9-Benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid methyl ester (56 mg) was hydrolyzed and isolated similarly as described in Example 50, Part D to afford 54 mg
20 of the title compound. FDMS m/e 392 (M^+); ESIMS m/e 393 (M^++1), 391 (M^+-1) NMR (300 MHz, d_6 -DMSO): δ 12.92 (br, 1H); 7.70 (m, 2H); 7.45 (t, $J=7.5$, 1H); 7.39 (br, 1H); 7.28-7.17 (m, 4H); 7.12 (d, $J=7.2$, 1H); 7.07 (d, $J=7.0$, 2H); 6.51 (dd, $J=8.8$, 2.7, 1H); 5.77 (s, 2H); 4.80 (s, 2H).

25 Elemental Analyses


Calculated: C 67.34; H 4.37; N 7.14
Found: C 66.92; H 4.49; N 6.77

X-12143A

-52-

EXAMPLE 4

Preparation of {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid



5 A. 9-[(3-Fluorophenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

40% Methanolic Triton B (2.06 mL, 4.53 mM) was slowly added dropwise to a solution of 5-carbomethoxy-1,2-dihydro-
 10 9H-carbazol-4(3H)-one (930.0 mg, 3.82 mM) in 5 mL of DMF at
 0 °C. After 5 minutes, 3-fluorobenzyl chloride (664.0 mg,
 4.59 mM) was added and the resultant mixture stirred at 0 °C
 for 3 h, then at room temperature for 20 hours. The mixture
 was diluted with ethyl acetate, washed three times with 1 N
 15 HCl, three times with H₂O, once with saturated brine, dried
 over anhydrous magnesium sulfate, filtered, and
 concentrated. The residue was purified by column
 chromatography on silica gel (elution with gradient
 methylene chloride/ethyl acetate) to afford 502.3 mg (37%)
 20 of the 9-[(3-fluorophenyl)methyl]-5-carbomethoxy-1,2-
 dihydrocarbazol-4(3H)-one as a yellow foam. ¹H NMR (CDCl₃)
 δ 7.4-7.2 (m, 4H), 6.9 (m, 1H), 6.7 (m, 2H), 5.35 (s, 2H),
 4.05 (s, 3H), 2.9 (t, 2H, J=6 Hz), 2.65 (t, 2H, J=6 Hz), and
 2.3 (m, 2H). IR (CHCl₃, cm⁻¹) 3050, 2950, 1725, 1654, 1464,
 25 1451, 1440, 1288 and 1119. MS (ES) m/e 350, 352.

X-12143A

-53-

Elemental Analyses for C₂₁H₁₈NO₃F:

Calculated: C, 71.78; H, 5.16; N, 3.99.

Found: C, 72.00; H, 4.95; N, 4.11.

5 B. 9-[(3-Fluorophenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

A solution of the 9-[(3-fluorophenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (434.0 mg, 1.23 mM) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (324.0 mg, 1.42 mM) in 20 mL of toluene was stirred between 70-80 °C for 5 h. The mixture was purified directly by column chromatography on silica gel (elution with methylene chloride) to afford 137.0 mg (32%) of the 9-[(3-fluorophenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a yellow foam. ¹H NMR (DMSO-d6) δ 10.2 (s, 1H), 7.7 (d, 1H, J=8 Hz), 7.4 (t, 1H, J=8 Hz), 7.3 (m, 2H), 7.2 (d, 1H, J=8 Hz), 7.1 (d, 1H, J=8 Hz), 7.05-6.85 (m, 3H), 6.6 (d, 1H, J=8 Hz), 5.65 (s, 2H), and 3.85 (s, 3H). IR (CHCl₃, cm⁻¹) 3200 (br), 1687, 1597, 1452, 1442, 1285, and 1267. MS (ES) m/e 348, 350.

Elemental Analyses for C₂₁H₁₆NO₃F:

Calculated: C, 72.20; H, 4.62; N, 4.01.

Found: C, 72.30; H, 4.66; N, 4.04.

25 C. 9-[(3-Fluorophenyl)methyl]-4-hydroxy-5-carbamoyl carbazole

A solution of the 9-[(3-fluorophenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole (130.8 mg, 0.37 mM) in 5 mL THF and 20 mL concentrated aqueous ammonium hydroxide was sonicated for 5 h at 40-50 °C. The mixture was diluted with ethyl acetate and acidified to pH 1 with 5 N HCl. The aqueous layer was extracted twice with ethyl acetate. The combined organic extracts were washed with saturated brine, dried over magnesium sulfate, filtered, and concentrated. The

X-12143A

-54-

residue was purified by column chromatography on silica gel (elution with gradient methylene chloride/ethyl acetate) to afford 57.4 mg (45%) of the 9-[(3-fluorophenyl)methyl]-4-hydroxy-5-carbamoyl carbazole as a white solid. ^1H NMR

5 (DMSO-d₆) δ 10.5 (s, 1H), 8.8 (br s, 1H), 8.4 (br s, 1H), 7.8 (dd, 1H, J=1 and 8 Hz), 7.5 (m, 2H), 7.3 (m, 2H), 7.15-7.0 (m, 2H), 6.95 (d, 1H, J=8 Hz), 6.85 (d, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), and 5.7 (s, 2H). IR (CHCl₃, cm⁻¹) 3431, 3200 (br), 1628, 1614, 1600, 1580, 1546, 1488, 1448, 1329, 1261, 10 and 776. MS (ES) m/e 333, 335.

Elemental Analyses for C₂₀H₁₅N₂O₂F:

Calculated: C, 71.85; H, 4.52; N, 8.38.

Found: C, 74.45; H, 6.01; N, 8.48.

15 D. {9-[(3-Fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, tert-butyl ester

40% Methanolic Triton B (0.086 mL, 0.19 mM) was added to a solution of the 9-[(3-fluorophenyl)methyl]-4-hydroxy-5-carbamoyl carbazole (51.9 mg, 0.155 mM) in 3 mL DMF at room 20 temperature. After 3 minutes, t-butyl bromoacetate (87.8 mg, 0.44 mM) was added and the resultant mixture stirred at room temperature for 5 hours. The mixture was diluted with ethyl acetate, washed four times with H₂O, and saturated brine, dried over magnesium sulfate, filtered, and concentrated.

25 The residue was purified by column chromatography on silica gel (elution with gradient methylene chloride/ethyl acetate) to afford 44.0 mg (63%) of the {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, tert-butyl ester as a white solid. ^1H NMR (DMSO-d₆) δ 7.6 (d, 1H, J=8 Hz),

30 7.5-6.8 (m, 10H), 6.55 (d, 1H, J=8 Hz), 5.7 (s, 2H), 4.8 (s, 2H), and 1.45 (s, 9H). IR (CHCl₃, cm⁻¹) 3450, 3400, 1746, 1674, 1592, 1457, 1369, and 1151. MS (FD) m/e 448.

X-12143A

-55-

Elemental Analyses for C₂₆H₂₅N₂O₄F:

Calculated: C, 69.63; H, 5.62; N, 6.25.

Found: C, 69.35; H, 5.44; N, 6.23.

5 E. {9-[(3-Fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid

A solution of the {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, tert-butyl ester (40.0 mg, 0.089 mM) in 2 mL of trifluoroacetic acid was
10 stirred at room temperature for 5 hours. The solvent was removed *in vacuo*. The residue was triturated with ethyl ether, then dried *in vacuo* to afford 35.0 mg (100%) of the {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid as a white powder. ¹H NMR (DMSO-d₆) δ 13.0 (br s, 1H), 7.75 (s, 1H), 7.6 (d, 1H, J=8 Hz), 7.5-7.25 (m, 5H), 7.2-6.8 (m, 4H), 6.6 (d, 1H, J=8 Hz), 5.7 (s, 2H), and 4.8 (s, 2H). IR (KBr, cm⁻¹) 3423, 3400, 1736, 1637, 1615, 1589, 1499, 1487, 1450, 1436, 1331, 1250, and 1156. MS (ES) m/e 391, 393.

20 Elemental Analyses for C₂₂H₁₇N₂O₄F:

Calculated: C, 67.34; H, 4.37; N, 7.14.


Found: C, 67.63; H, 4.22; N, 7.35.

X-12143A

-56-

EXAMPLE 5

Preparation of {9-[(3-Chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid



- 5 A. 9-[(3-Chlorophenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

A suspension of 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one (527.0 mg, 2.17 mM), 3-chlorobenzyl bromide (802.2 mg, 3.90 mM), a catalytic amount of sodium iodide (ca. 1 mg), and potassium carbonate (500.0 mg, 3.62 mM) was stirred at room temperature for 150 hours. The mixture was diluted with ethyl acetate, washed five times with H₂O, once with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with gradient methylene chloride/ethyl acetate) to afford 537.1 mg (67%) of the 9-[(3-chlorophenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one as a yellow foam. ¹H NMR (CDCl₃) δ 7.5-7.2 (m, 5H), 7.1 (s, 1H), 6.85 (m, 1H), 5.35 (s, 2H), 4.05 (s, 3H), 2.9 (t, 2H, J=6 Hz), 2.65 (t, 2H, J=6 Hz), and 2.3 (m, 2H). IR (CHCl₃, cm⁻¹) 3050, 2950, 1725, 1654, 1464, 1444, 1432, 1288 and 1120. MS (ES) m/e 366, 368, 370.

Elemental Analyses for C₂₁H₁₈NO₃Cl:

Calculated: C, 68.57; H, 4.93; N, 3.81.
 25 Found: C, 68.61; H, 4.92; N, 3.70.

X-12143A

-57-

B. 9-[(3-Chlorophenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

A solution of the 9-[(3-chlorophenyl)methyl]-5-
5 carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (480.5 mg, 1.31
mM) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (325.7 mg,
1.43 mM) in 50 mL of toluene was stirred between 70-80 °C
for 3 hours. The mixture was purified directly by column
chromatography on silica gel (elution with methylene
10 chloride) to afford 172.6 mg (36%) of the 9-[(3-
chlorophenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a
yellow foam. ^1H NMR (CDCl_3) δ 10.4 (s, 1H), 8.05 (d, 1H,
 $J=8$ Hz), 7.6 (d, 1H, $J=8$ Hz), 7.4 (m, 2H), 7.3-7.1 (m, 3H),
6.9-6.7 (m, 3H), 5.55 (s, 2H), and 4.15 (s, 3H). IR (CHCl_3 ,
15 cm^{-1}) 3200 (br), 1684, 1598, 1442, 1428, 1331, 1285, and
1267. MS (ES) m/e 364, 366, 368.

Elemental Analyses for $\text{C}_{21}\text{H}_{16}\text{NO}_3\text{Cl}$:

Calculated: C, 68.95; H, 4.41; N, 3.83.

Found: C, 69.23; H, 4.52; N, 3.88.

20

C. 9-[(3-Chlorophenyl)methyl]-4-hydroxy-5-carbamoyl carbazole

A solution of the 9-[(3-chlorophenyl)methyl]-4-hydroxy-
5-carbomethoxy carbazole (156.2 mg, 0.43 mM) in 5 mL THF and
25 20 mL concentrated aqueous ammonium hydroxide was sonicated
for 5 hours at 40-50 °C. The mixture was diluted with ethyl
acetate and acidified to pH 1 with 5 N HCl. The aqueous
layer was extracted twice with ethyl acetate. The combined
organic extracts were washed with saturated brine, dried
30 over magnesium sulfate, filtered, and concentrated. The
residue was purified by column chromatography on silica gel
(elution with gradient methylene chloride/ethyl acetate) to
afford 69.7 mg (47%) of the 9-[(3-chlorophenyl)methyl]-4-
hydroxy-5-carbamoyl carbazole as a white solid. ^1H NMR

X-12143A

-58-

(DMSO-d₆) δ 10.5 (s, 1H), 8.8 (br s, 1H), 8.4 (br s, 1H), 7.8 (dd, 1H, J=1 and 8 Hz), 7.45 (m, 2H), 7.3 (m, 3H), 7.2 (s, 1H), 7.1 (d, 1H, J=8 Hz), 6.95 (s, 1H), 6.6 (d, 1H, J=8 Hz), and 5.7 (s, 2H). IR (CHCl₃, cm⁻¹) 3433, 3202 (br), 1630, 1600, 1580, 1564, 1433, 1330, 1261, and 776. MS (ES) m/e 349, 351, 353.

Elemental Analyses for C₂₀H₁₅N₂O₂Cl:

Calculated: C, 68.48; H, 4.31; N, 7.99.
Found: C, 68.64; H, 4.55; N, 7.93.

10

D. {9-[(3-Chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, tert-butyl ester

40% Methanolic Triton B (0.053 mL, 0.12 mM) was added to a solution of the 9-[(3-chlorophenyl)methyl]-4-hydroxy-5-carbamoyl carbazole (33.2 mg, 0.12 mM) in 2 mL DMF at room temperature. After 3 minutes, t-butyl bromoacetate (53.8 mg, 0.27 mM) was added and the resultant mixture stirred at room temperature for 20 h. The mixture was diluted with ethyl acetate, washed four times with H₂O, once with saturated brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with gradient methylene chloride/ethyl acetate) to afford 42.1 mg (95%) of the {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, tert-butyl ester as a white solid. ¹H NMR (DMSO-d₆) δ 7.6 (d, 1H, J=8 Hz), 7.5-6.8 (m, 10H), 6.55 (d, 1H, J=8 Hz), 5.7 (s, 2H), 4.8 (s, 2H), and 1.45 (s, 9H). IR (CHCl₃, cm⁻¹) 3450, 3400, 1744, 1676, 1591, 1457, 1369, and 1150. MS (FD) m/e 464, 466.

30 Elemental Analyses for C₂₆H₂₅N₂O₄Cl:

Calculated: C, 67.17; H, 5.42; N, 6.03.
Found: C, 67.17; H, 5.65; N, 5.97.

X-12143A

-59-

E. {9-[{(3-Chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid

A solution of the {9-[{(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, tert-butyl ester

5 (35.6 mg, 0.077 mM) in 2 mL of trifluoroacetic acid was stirred at room temperature for 6 hours. The solvent was removed *in vacuo*. The residue was triturated with ethyl acetate, then dried *in vacuo* to afford 31.4 mg (100%) of the {9-[{(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid as a white powder.

¹H NMR (DMSO-d₆)

δ 13.0 (br s, 1H), 7.75 (s, 1H), 7.6 (d, 1H, J=8 Hz), 7.4-7.25 (m, 7H), 7.2 (d, 1H, J=8 Hz), 7.0 (br t, 1H), 6.6 (d, 1H, J=8 Hz), 5.7 (s, 2H), and 4.8 (s, 2H). IR (KBr, cm⁻¹) 3456, 3416, 3335, 1735, 1638, 1617, 1580, 1499, 1452, 1431, 1431, 1329, 1255, 1157, 772, 764, and 717. MS (ES) m/e 407, 409, 411.

Elemental Analyses for C₂₂H₁₇N₂O₄Cl:


Calculated: C, 64.63; H, 4.19; N, 6.85.

Found: C, 64.55; H, 4.12; N, 6.74.

20

EXAMPLE 6

Preparation of {9-[{(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt



25

X-12143A

-60-

A. 9-[(3-Trifluoromethylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

40% Methanolic Triton B (2.18 mL, 4.8 mM) was slowly added dropwise to a solution of 5-carbomethoxy-1,2-dihydro-
 5 9H-carbazol-4(3H)-one (973 mg, 4.0 mM) in 10 mL of DMF at -10 °C. After 30 minutes, 3-(trifluoromethyl)benzyl chloride (1.53 g, 6.0 mM) and sodium iodide (900 mg, 6.0 mM) were added and the resultant mixture stirred at room temperature for 25 hours. The mixture was diluted with ethyl acetate,
 10 washed five times with H₂O, 1 N HCl, H₂O, sat NaHCO₃, and saturated brine, dried over anhydrous magnesium sulfate, filtered, concentrated, and dried *in vacuo*. The residue was purified by column chromatography on silica gel (elution with gradient methylene chloride/ethyl acetate) to afford
 15 1.02 g (63%) of the 9-[(3-trifluoromethylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one as a tan solid.
¹H NMR (CDCl₃) δ 7.6 (d, 1H, J=8 Hz), 7.45-7.2 (m, 5H), 7.0 (d, 1H, J=8 Hz), 5.4 (s, 2H), 4.05 (s, 3H), 2.85 (t, 2H, J=6 Hz), 2.6 (t, 2H, J=6 Hz), and 2.2 (m, 2H). IR (KBr, cm⁻¹)
 20 1727 and 1652. MS (ES) m/e 400, 402.

Elemental Analyses for C₂₂H₁₈NO₃F₃:

Calculated: C, 65.83; H, 4.52; N, 3.49; F, 14.20.
 Found: C, 65.63; H, 4.58; N, 3.39; F, 14.14.

25 B. 9-[(3-Trifluoromethylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

A solution of the 9-[(3-trifluoromethylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (1.21 g, 3.00 mM) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (764 mg, 3.3 mM) in 25 mL of toluene was stirred between 80-90 °C for 7 hours. The mixture was purified directly by column chromatography on silica gel (elution with methylene chloride) to afford 340.0 mg (28%) of the 9-[(3-

X-12143A

-61-

trifluoromethylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a yellow solid. ^1H NMR (CDCl_3) δ 10.35 (s, 1H), 8.0 (d, 1H, $J=8$ Hz), 7.6-7.3 (m, 6H), 7.05 (d, 1H, $J=8$ Hz), 6.85 (m, 2H), 5.6 (s, 2H), and 4.1 (s, 3H). IR (CHCl_3 , cm^{-1}) 5 3378 and 1712. MS (ES) m/e 398, 400.

Elemental Analyses for $\text{C}_{22}\text{H}_{16}\text{NO}_3\text{F}_3$:

Calculated: C, 66.17; H, 4.04; N, 3.51.

Found: C, 66.99; H, 4.12; N, 3.53; F.

10 C. 9-[(3-Trifluoromethylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole

A solution of the 9-[(3-trifluoromethylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole (250 mg, 0.625 mM) in 5 mL THF and 20 mL concentrated aqueous ammonium hydroxide was 15 sonicated for 30 h at 40-50 °C. The mixture was diluted with ethyl acetate and acidified to pH 1 with 5 N HCl. The aqueous layer was extracted three times with ethyl acetate. The combined organic extracts were washed with saturated brine, dried over magnesium sulfate, filtered, and 20 concentrated. The residue was purified by column chromatography on silica gel (elution with gradient methylene chloride/ethyl acetate) to afford 120 mg (50%) of the 9-[(3-trifluoromethylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole as a white solid. ^1H NMR (DMSO-d_6) δ 25 10.5 (s, 1H), 8.8 (br s, 1H), 8.4 (br s, 1H), 7.8 (d, 1H, $J=8$ Hz), 7.6-7.5 (m, 5H), 7.3 (t, 1H, $J=8$ Hz), 7.15 (d, 1H, $J=8$ Hz), 7.1 (d, 1H, $J=8$ Hz), 6.6 (d, 1H, $J=8$ Hz), and 5.8 (s, 2H). IR (KBr , cm^{-1}) 3429, 3206, and 1630. MS (ES) m/e 383, 385.

30 Elemental Analyses for $\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_2\text{F}_3$:

Calculated: C, 65.62; H, 3.93; N, 7.29.

Found: C, 67.50; H, 4.00; N, 7.19.

X-12143A

-62-

D. {9-[(3-Trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester

40% Methanolic Triton B (0.18 mL, 0.4 mM) was added to
 5 a solution of the 9-[(3-trifluoromethylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole (115 mg, 0.3 mM) in 5 mL DMF at room temperature. After 15 minutes, methyl bromoacetate (95 mg, 0.6 mM) was added and the resultant mixture stirred at room temperature for 22 hours. The mixture was diluted
 10 with ethyl acetate, washed four times with H₂O, 1 N HCl, H₂O, sat. NaHCO₃, and saturated brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with ethyl acetate) to afford 120 mg (88%) of the {9-[(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester as a white solid. ¹H NMR (CDCl₃) δ 7.5-7.2 (m, 7H), 7.1 (d, 1H, J=8 Hz), 7.0 (d, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 6.4 (br s, 1H), 6.0 (br s, 1H), 5.55 (s, 2H), 4.9 (s, 2H), and 3.9 (s, 3H). IR (KBr, 20 cm⁻¹) 1763 and 1673. MS (ES) m/e 457.

Elemental Analyses for C₂₄H₁₉N₂O₄F₃:

Calculated: C, 63.16; H, 4.20; N, 6.14.

Found: C, 61.37; H, 4.19; N, 5.77.

25 E. {9-[(3-Trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt.

A solution of the {9-[(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester (91 mg, 0.153 mM) and 0.22 mL (0.22 mM) of 1 N NaOH in 8 mL of
 30 ethanol was stirred for 17 h at 25 °C. The ethanol was removed *in vacuo*. The resultant white precipitate was collected by filtration, washed with small amounts of EtOH and diethyl ether, then dried *in vacuo* to afford 75 mg (81%)

X-12143A

-63-


of the {9-[(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt as a white powder. ^1H NMR (DMSO-d₆) δ 7.65 (s, 1H), 7.6 (m, 4H), 7.45 (t, 1H, J=8 Hz), 7.35 (t, 1H, J=8 Hz), 7.3 (t, 1H, J=8 Hz), 7.2 (d, 1H, J=8 Hz), 7.1 (d, 1H, J=8 Hz), 7.05 (d, 1H, J=8 Hz), 6.5 (d, 1H, J=8 Hz), 5.75 (s, 2H), and 4.3 (s, 2H). IR (KBr, cm⁻¹) 1665 and 1618. MS (ES) m/e 441, 443.

Elemental Analyses for C₂₃H₁₆N₂O₄F₃Na:

Calculated: C, 59.49; H, 3.47; N, 6.03.
 10 Found: C, 60.69; H, 3.78; N, 5.75.

EXAMPLE 7

Preparation of {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt



15

A. 9-[(2-Methylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

A suspension of 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one (870 mg, 3.58 mM), *a*-bromo-*o*-xylene (662 mg, 3.58 mM), and potassium carbonate (500 mg, 3.61 mM) in 20 mL DMF was stirred at room temperature for 20 hours. The mixture was diluted with ethyl acetate, washed with H₂O and saturated brine, dried over anhydrous magnesium sulfate, filtered, concentrated to afford 1.21 g (98%) of the 9-[(2-methylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-

X-12143A

-64-

4(3H)-one as a dark oil. ^1H NMR (DMSO-d₆) δ 7.5-7.2 (m, 4H), 7.15 (t, 1H, J=8 Hz), 7.0 (t, 1H, J=8 Hz), 6.15 (d, 1H, J=8 Hz), 5.55 (s, 2H), 3.85 (s, 3H), 2.6 (m, 2H), 2.4 (m, 2H), 2.4 (s, 3H), and 2.1 (m, 2H). IR (CHCl₃, cm⁻¹) 3010, 5 2952, 1724, 1671, 1653, 1604, 1460, 1444, 1290, 1174, and 1122. MS (ES) m/e 348.5.

Elemental Analyses for C₂₂H₂₁NO₃:

Calculated: C, 76.08; H, 6.05; N, 4.03.

Found C, 73.33; H, 6.36; N, 4.30.

10

B. 9-[(2-Methylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

A solution of the 9-[(2-methylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (1.2 g, 3.5 mM) 15 and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (800 mg, 3.6 mM) in 70 mL of toluene was stirred at 80-90 °C for 5 hours. The mixture was purified directly by column chromatography on silica gel (elution with methylene chloride) to afford 260 mg (22%) of the 9-[(2-methylphenyl)methyl]-4-hydroxy-5-20 carbomethoxy carbazole as a yellow solid. ^1H NMR (DMSO-d₆) δ 10.25 (s, 1H), 7.5 (d, 1H, J=8 Hz), 7.4 (t, 1H, J=8 Hz), 7.3-7.1 (m, 4H), 6.9 (m, 2H), 6.6 (d, 1H, J=8 Hz), 6.1 (d, 1H, J=8 Hz), 5.65 (s, 2H), 3.8 (s, 3H), and 2.5 (s, 3H). IR (KBr, cm⁻¹) 3200, 1672, 1440, 1426, 1332, 1302, 1265, 25 1216, 1141, 761, 749, and 718. MS (ES) m/e 344, 346.

Elemental Analyses for C₂₂H₁₉NO₃:

Calculated: C, 76.52; H, 5.51; N, 4.06.

Found: C, 76.44; H, 5.66; N, 3.94.

30

X-12143A

-65-

C. 9-[(2-Methylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole

A solution of the 9-[(2-methylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole (260 mg, 0.75 mM) in 10 mL THF and 5 30 mL concentrated aqueous ammonium hydroxide was sonicated for 5 hours at 40-50 °C. The mixture was diluted with ethyl acetate and acidified to pH 1 with 5 N HCl. The aqueous layer was extracted three times with ethyl acetate. The combined organic extracts were washed with H₂O and saturated 10 brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with gradient hexanes/ethyl acetate) to afford 90 mg (36%) of the 9-[(2-methylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole as a 15 tan solid. ¹H NMR (DMSO-d6) δ 10.5 (s, 1H), 8.8 (br s, 1H), 8.4 (br s, 1H), 7.7 (m, 1H), 7.5 (m, 2H), 7.3 (m, 2H), 7.1 (t, 1H, J=8 Hz), 6.95 (d, 1H, J=8 Hz), 6.85 (t, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 5.95 (d, 1H, J=8 Hz), 5.7 (s, 2H), and 2.5 (s, 3H). IR (KBr, cm⁻¹) 3451, 3191, 1627, 1600, 20 1584, 1562, 1435, 1329, 1322, 1263, and 774. MS (ES) m/e 329, 331.

Elemental Analyses for C₂₁H₁₈N₂O₂:

Calculated: C, 76.36; H, 5.45; N, 8.48.

Found: C, 75.66; H, 5.79; N, 8.07.

25

D. {9-[(2-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester

40% Methanolic Triton B (0.45 mL, 0.99 mM) was added to a solution of the 9-[(2-methylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole (80 mg, 0.24 mM) in 8 mL DMF at room temperature. After 3 minutes, methyl bromoacetate (115 mg, 0.72 mM) was added and the resultant mixture stirred at room temperature for 48 hours. The mixture was diluted with

X-12143A

-66-

ethyl acetate, washed with H₂O, 1 N HCl, H₂O, and saturated brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with ethyl acetate) to afford 80 mg (82%) of the {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester as a white solid. ¹H NMR (DMSO-d6) δ 7.56 (br s, 1H), 7.5-7.1 (m, 9H), 6.9 (t, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 5.65 (s, 2H), 4.9 (s, 2H), 3.8 (s, 3H), and 2.5 (s, 3H). IR (KBr, cm⁻¹) 3367, 3153, 1760, 1740, 1672, 1644, 1619, 1591, 1578, 1498, 1456, 1425, 1327, 1200, 1153, 1109, 1100, and 777. MS (FD) m/e 402.

Elemental Analyses for C₂₄H₂₂N₂O₄:

Calculated: C, 71.64; H, 5.47; N, 6.96.
15 Found: C, 71.51; H, 5.56; N, 6.67.

E. {9-[(2-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt

A suspension of the {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester (15.5 mg, 0.039 mM) and 0.04 mL (0.04 mM) of 1 N NaOH in 5 mL of ethanol was stirred for 24 hours at 25 °C. The resultant white precipitate was collected by filtration, washed with a small amount of EtOH, then dried *in vacuo* to afford 10 mg (63%) of the {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt as a white powder. ¹H NMR (DMSO-d6) δ 7.55 (br s, 1H), 7.5-7.0 (m, 7H), 6.9 (d, 1H, J=8 Hz), 6.85 (t, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 6.2 (d, 1H, J=8 Hz), 5.6 (s, 2H), 4.35 (s, 2H), and 2.5 (s, 3H). IR (KBr, cm⁻¹) 3390, 1656, 1613, 1595, 1573, 1498, 1455, 1408, 1325, 1332, and 719. MS (ES) m/e 387, 389.

X-12143A

-67-

Elemental Analyses for C₂₃H₁₉N₂O₄:


Calculated: C, 67.32; H, 4.63; N, 6.83.

Found: C, 64.72; H, 4.44; N, 6.40.

5

EXAMPLE 8

Preparation of {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt



- 10 A. 9-[(3-Methylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

A suspension of 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one (870 mg, 3.58 mM), *a*-bromo-*m*-xylene (662 mg, 3.58 mM), and potassium carbonate (500 mg, 3.61 mM) in 20 mL DMF 15 was stirred at room temperature for 16 hours. The mixture was diluted with ethyl acetate, washed with H₂O and saturated brine, dried over anhydrous magnesium sulfate, filtered, concentrated to afford 1.18 g (95%) of the 9-[(3-methylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one as a dark oil. ¹H NMR (DMSO-d₆) δ 7.65 (dd, 1H, J=1 and 8 Hz), 7.3-7.1 (m, 3H), 7.05 (d, 1H, J=8 Hz), 7.0 (s, 1H), 6.85 (d, 1H, J=8 Hz), 5.5 (s, 2H), 3.8 (s, 3H), 3.0 (m, 2H), 2.45 (m, 2H), 2.3 (s, 3H), and 2.1 (m, 2H). IR

X-12143A

-68-

(CHCl₃, cm⁻¹) 3010, 2953, 1724, 1652, 1605, 1465, 1442, 1288, 1174, and 1119. MS (ES) m/e 348.5.

Elemental Analyses for C₂₂H₂₁NO₃:

Calculated: C, 76.08; H, 6.05; N, 4.03.
 5 Found: C, 74.53; H, 6.03; N, 3.68.

B. 9-[(3-Methylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

A solution of the 9-[(3-methylphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (1.18 g, 3.4 mM) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (800 mg, 3.6 mM) in 70 mL of toluene was stirred at 80-90 °C for 6 hours. The mixture was purified directly by column chromatography on silica gel (elution with methylene chloride) to afford 15 300 mg (26%) of the 9-[(3-methylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a yellow solid. ¹H NMR (DMSO-d₆) δ 10.2 (s, 1H), 7.65 (d, 1H, J=8 Hz), 7.35 (t, 1H, J=8 Hz), 7.25 (t, 1H, J=8 Hz), 7.2-7.0 (m, 4H), 6.9 (m, 2H), 6.6 (d, 1H, J=8 Hz), 5.6 (s, 2H), 3.85 (s, 3H), and 2.2 (s, 3H).
 20 IR (KBr, cm⁻¹) 3200, 1673, 1596, 1440, 1426, 1394, 1265, 1216, 1152, 750, 711, and 694. MS (ES) m/e 344, 346.

Elemental Analyses for C₂₂H₁₉NO₃:

Calculated: C, 76.52; H, 5.51; N, 4.06.
 25 Found: C, 76.22; H, 5.55; N, 3.97.

C. 9-[(3-Methylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole

A solution of the 9-[(3-methylphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole (300 mg, 0.87 mM) in 10 mL THF and 30 30 mL concentrated aqueous ammonium hydroxide was sonicated for 5 hours at 40-50 °C. The mixture was diluted with ethyl acetate and acidified to pH 1 with 5 N HCl. The aqueous

X-12143A

-69-

layer was extracted three times with ethyl acetate. The combined organic extracts were washed with H₂O and saturated brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with gradient hexanes/ethyl acetate) to afford 114 mg (40%) of the 9-[(3-methylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole as an off-white solid. ¹H NMR (DMSO-d6) δ 10.5 (s, 1H), 8.8 (br s, 1H), 8.4 (br s, 1H), 7.8 (dd, 1H, J=1 and 8 Hz), 7.4 (m, 2H), 7.3 (t, 1H, J=8 Hz), 7.15-7.0 (m, 3H), 6.85 (d, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 5.95 (d, 1H, J=8 Hz), 5.65 (s, 2H), and 2.25 (s, 3H). IR (KBr, cm⁻¹) 3434, 3203, 1629, 1599, 1579, 1552, 1443, 1330, 1262, 1214, and 776. MS (ES) m/e 329, 331.

Elemental Analyses for C₂₁H₁₈N₂O₂:

Calculated: C, 76.36; H, 5.45; N, 8.48.
Found: C, 77.56; H, 5.67; N, 8.26.

D. {9-[(3-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester

40% Methanolic Triton B (0.45 mL, 0.99 mM) was added to a solution of the 9-[(3-methylphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole (100 mg, 0.30 mM) in 8 mL DMF at room temperature. After 3 minutes, methyl bromoacetate (115 mg, 0.72 mM) was added and the resultant mixture stirred at room temperature for 24 hours. The mixture was diluted with ethyl acetate, washed with H₂O, and saturated brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with ethyl acetate) to afford 80 mg (66%) of the {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester as a white solid. ¹H NMR (DMSO-d6) δ 7.6 (d, 1H, J=8 Hz), 7.55 (br s, 1H), 7.45-7.0 (m, 8H), 6.9

X-12143A

-70-

(d, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 5.65 (s, 2H), 4.9 (s, 2H), 3.75 (s, 3H), and 2.2 (s, 3H). IR (KBr, cm⁻¹) 3367, 3157, 1760, 1642, 1589, 1499, 1455, 1424, 1328, 1216, 1151, 1102, 772, and 714. MS (FD) m/e 402.

5 Elemental Analyses for C₂₄H₂₂N₂O₄:

Calculated: C, 71.64; H, 5.47; N, 6.96.

Found: C, 71.01; H, 5.60; N, 6.66.

E. {9-[(3-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt
10

A suspension of the {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester (15.8 mg, 0.039 mM) and 0.04 mL (0.04 mM) of 1 N NaOH in 5 mL of ethanol was stirred for 24 h at 25 °C. The resultant white
15 precipitate was collected by filtration, washed with a small amount of EtOH, then dried *in vacuo* to afford 10 mg (62%) of the {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt as a white powder. ¹H NMR (DMSO-d6) δ 7.55 (d, 1H, J=8 Hz), 7.5-7.0 (m, 9H), 6.85 (d, 2H, J=8 Hz), 6.55 (d, 1H, J=8 Hz), 5.6 (s, 2H), 4.35 (s, 2H), and 2.2 (s, 3H). IR (KBr, cm⁻¹) 3390, 1656, 1613, 1595, 1573, 1498, 1455, 1408, 1325, 1332, and 719. MS (ES) m/e 387, 389.


Elemental Analyses for C₂₃H₁₉N₂O₄Na:
25 Calculated: C, 67.32; H, 4.63; N, 6.83.
Found: C, 61.20; H, 4.64; N, 6.06.

X-12143A

-71-

EXAMPLE 9

Preparation of {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt



5 A. 9-[(3-Trifluoromethoxyphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

A suspension of 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one (935 mg, 3.85 mM), 3-trifluoromethoxybenzyl bromide (1.0 g, 3.93 mM), and potassium carbonate (531 mg, 3.85 mM) in 20 mL DMF was stirred at room temperature for 17 hours. The mixture was diluted with ethyl acetate, washed with H₂O and saturated brine, dried over anhydrous magnesium sulfate, filtered, concentrated to afford 1.6 g (100%) of the 9-[(3-trifluoromethoxyphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one as a foam. ¹H NMR (DMSO-d₆) δ 7.7 (dd, 1H, J=1 and 8 Hz), 7.45 (t, 1H, J=8 Hz), 7.3-7.1 (m, 4H), 7.05 (d, 1H, J=8 Hz), 5.6 (s, 2H), 3.8 (s, 3H), 3.0 (m, 2H), 2.45 (m, 2H), and 2.1 (m, 2H). IR (CHCl₃, cm⁻¹) 1729, 1647, 1439, 1259, 1176, and 1116. MS (ES) m/e 418.

20 Elemental Analyses for C₂₂H₁₈NO₄F₃:

Calculated: C, 63.31; H, 4.32; N, 3.36.

Found: C, 63.12; H, 4.35; N, 3.31.

X-12143A

-72-

B. 9-[(3-Trifluoromethoxyphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

A solution of the 9-[(3-trifluoromethoxyphenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (0.75 g, 1.8 mM) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (490 mg, 2.16 mM) in 70 mL of toluene was stirred at reflux for 6 hours. The mixture was purified directly by column chromatography on silica gel (elution with methylene chloride) to afford 300 mg (40%) of the 9-[(3-trifluoromethoxyphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a yellow solid. ^1H NMR (DMSO-d₆) δ 10.25 (s, 1H), 7.7 (d, 1H, J=8 Hz), 7.5-7.0 (m, 8H), 6.6 (d, 1H, J=8 Hz), 5.7 (s, 2H), and 3.85 (s, 3H). IR (KBr, cm⁻¹) 3200, 1673, 1441, 1268, 1217, 1173, and 753. MS (ES) m/e 414, 416.

Elemental Analyses for C₂₂H₁₆NO₃F₃

Calculated:	C, 63.61; H, 3.86; N, 3.37.
Found:	C, 63.40; H, 3.99; N, 3.43.

C. 9-[(3-Trifluoromethoxyphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole

A solution of the 9-[(3-trifluoromethoxyphenyl)methyl]-4-hydroxy-5-carbomethoxy carbazole (260 mg, 0.62 mM) in 10 mL THF and 30 mL concentrated aqueous ammonium hydroxide was stirred vigorously for 132 hours. The mixture was diluted with ethyl acetate and acidified to pH 1 with 5 N HCl. The aqueous layer was extracted three times with ethyl acetate. The combined organic extracts were washed with H₂O and saturated brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (elution with gradient hexanes/ethyl acetate) to afford 150 mg (60%) of the 9-[(3-trifluoromethoxyphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole as an off-white solid. ^1H NMR (DMSO-d₆) δ 10.5

X-12143A

-73-

(s, 1H), 8.8 (br s, 1H), 8.4 (br s, 1H), 7.85 (dd, 1H, J=1 and 8 Hz), 7.5-7.15 (m, 5H), 7.1 (d, 1H, J=8 Hz), 7.0 (d, 1H, J=8 Hz), 6.6 (d, 1H, J=8 Hz), 5.95 (d, 1H, J=8 Hz), and 5.65 (s, 2H). IR (KBr, cm⁻¹) 3431, 3203, 1629, 1601, 1580, 5 1548, 1446, 1330, 1261, 1215, and 777. MS (ES) m/e 399, 401.

Elemental Analyses for C₂₁H₁₅N₂O₂F₃:

Calculated: C, 63.00; H, 3.75; N, 7.0.

Found: C, 63.15; H, 4.07; N, 6.84.

10 D. {9-[(3-Trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester

40% Methanolic Triton B (0.15 mL, 0.34 mM) was added to a solution of the 9-[(3-trifluoromethoxyphenyl)methyl]-4-hydroxy-5-carbamoyl carbazole (115 mg, 0.28 mM) in 8 mL DMF at room temperature. After 3 minutes, methyl bromoacetate (65 mg, 0.41 mM) was added and the resultant mixture stirred at room temperature for 23 hours. The mixture was diluted with ethyl acetate, washed with H₂O, and saturated brine, dried over magnesium sulfate, filtered, and concentrated. 15 The residue was purified by column chromatography on silica gel (elution with ethyl acetate) to afford 112 mg (83%) of the (9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid, methyl ester as a white solid. ¹H NMR (DMSO-d6) δ 7.6 (d, 1H, J=8 Hz), 7.55 (br s, 1H), 7.5-7.0 (m, 9H), 6.6 (d, 1H, J=8 Hz), 5.7 (s, 2H), 4.9 (s, 2H), and 3.75 (s, 3H). IR (KBr, cm⁻¹) 3488, 3141, 1763, 1674, 1501, 1444, 1269, 1215, 1178, 1102, 772, and 714. MS (FD) m/e 472.

Elemental Analyses for C₂₄H₁₅N₂O₅F₃:

30 Calculated: C, 61.02; H, 4.03; N, 5.93.

Found: C, 61.05; H, 4.17; N, 5.81.

X-12143A

-74-

E. {9-[(3-Trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt

A suspension of the {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, methyl ester (22.4 mg, 0.047 mM) and 0.065 mL (0.065 mM) of 1 N NaOH in 5 mL of ethanol was stirred for 24 hours at 25 °C. The solvent was removed in vacuo and the residue suspended in EtOH. The resultant white precipitate was collected by filtration, washed with a small amount of EtOH, then dried in vacuo to afford 9 mg (41%) of the {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt as a white powder. MS (ES) m/e 457, 459.

15

Example 10

Preparation of [9-benzyl-5-carbamoyl-1-methylcarbazol-4-yl]oxyacetic acid

A. Preparation of 5-carbamoyl-4-methoxy-1-methylcarbazole

A solution of 0.805 g of 9-benzyl-5-methoxy-8-methyl-1,2,3,4-tetrahydrocarbazole-4-carboxamide in 24 ml of carbitol was treated with 1.1 g of 5% palladium on carbon and was refluxed for 6 hours open to the air. After cooling, the solution was filtered thorough a pad of celite and the pad was washed with ethyl acetate. The filtrates were diluted with ether and washed four times with water and dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel using methanol/0-4% in dichloromethane to afford 0.166 g (28%) of debenzylated carbazole. ESIMS m/e 255 (M⁺+1), 253 (M⁺-1) NMR (300 MHz, CDCl₃): δ 8.13 (br, 1H); 7.51 (d, J=8.1, 1H); 7.40 (t, J=7.6, 1H); 7.32 (d, J=7.2, 1H); 7.18 (d, J=7.8, 1H); 6.60 (d, J=8.0, 1H); 5.68 (br, 2H); 3.99 (s, 3H); 2.50 (s 3H).

X-12143A

-75-

B. Preparation of 9-benzyl-5-carbamoyl-4-methoxy-1-methylcarbazole

A solution of 0.148 g of 5-carbamoyl-4-methoxy-1-methylcarbazole in 1.1 ml of dimethylformamide was added to 0.026 g of sodium hydride (60% in mineral oil) in 0.4 ml of dimethylformamide and stirred for 60 minutes at room temperature. Benzyl bromide (0.076 ml) was then added and the reaction was stirred overnight. The reaction mixture was poured into 20 ml of saturated ammonium chloride solution and then extracted twice with ethyl acetate. The extracts were washed with water and then with brine, dried over magnesium sulfate and concentrated. The residue was rinsed with hexane and dissolved in dichloromethane, filtered and concentrated to afford 0.21 g of the subtitle compound. FDMS *m/e* 344 (M^+)

Elemental Analyses

Calculated: C 76.72; H 5.85; N 8.13

Found: C 75.20; H 6.19; N 7.54

20

C. Preparation of [9-benzyl-5-carbamoyl-1-methylcarbazol-4-yl]oxyacetic acid methyl ester]

A solution of 0.23 g of 9-benzyl-5-carbamoyl-4-methoxy-1-methylcarbazole in 4 ml of dimethylformamide was added to a 1 ml solution of sodium ethane thiolate (prepared from 0.116 g of sodium hydride 60% dispersion and 0.22 ml of ethanethiol under nitrogen) and heated at 110°C for 15 hours. The reaction mixture was cooled, poured into 20 ml of 1 N HCl and extracted twice with ethyl acetate. The extracts were washed twice with water and then with brine, dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel using methanol/0-1% in dichloromethane to afford 0.146 g (66%) of the demethylated

X-12143A

-76-

intermediate. A solution of 0.146 g of this intermediate in 1.5 ml of dimethylformamide was added to 0.021 g of sodium hydride (60% in mineral oil) in 0.5 ml of dimethylformamide. After stirring for 10 minutes at room temperature, 0.054 ml 5 of methyl bromoacetate was added. After stirring for 5 hours at room temperature, the reaction mixture was poured into water and extracted twice with ethyl acetate. The extracts were washed with water and then with brine, dried over magnesium sulfate and concentrated. The residue was 10 chromatographed on silica gel using methanol/ 0-2% in dichloromethane to afford 0.10 g (56%) of the subtitle compound. mp. 228-230°C ESIMS m/e 403 ($M^{+}+1$)

Elemental Analyses

Calculated: C 71.63; H 5.51; N 6.96
15 Found: C 71.34; H 5.60; N 6.70

D. Preparation of [9-benzyl-5-carbamoyl-1-methylcarbazol-4-yl]oxyacetic acid

A slurry of 32 mg (0.0795 mmol) of [9-benzyl-5-20 carbamoyl-1-methylcarbazol-4-yl]oxyacetic acid methyl ester in 1 ml of tetrahydrofuran and 3.5 ml of methanol was treated with 0.3 ml of an aqueous 2 N sodium hydroxide solution and stirred overnight at room temperature. The solvent was evaporated and the residue was partitioned 25 between 1:1 ethyl acetate/tetrahydrofuran and 0.2 N HCl solution. After another extraction with 1:1 ethyl acetate/tetrahydrofuran, the extracts were washed with brine, dried over magnesium sulfate and concentrated to afford (27 mg) of the title compound. mp. 253-254°C. ESIMS 30 m/e 389 ($M^{+}+1$), 387 ($M^{+}-1$) NMR (300 MHz, d_6 -DMSO): δ 12.83 (br, 1H); 7.75 (br, 1H); 7.53 (d, $J=8.2$, 1H); 7.41-7.34 (m, 2H); 7.28-7.17 (m, 3H); 7.07 (m, 2H); 6.90 (d,

X-12143A

-77-

J=7.2, 2H); 6.49 (d, J=8.1, 1H); 5.89 (s, 2H); 4.79 (s, 2H); 2.52 (s, 3H).

Example 11

Preparation of [9-benzyl-4-carbamoyl-8-fluoro-1,2,3,4-tetrahydrocarbazol-5-yl]oxyacetic acid

A. Preparation of (2-chloro-4-fluorophenyl)- ethyl carbonate

A solution of 19.16 g of 2-chloro-4-fluorophenol in 10 65.4 ml of 2 N aqueous sodium hydroxide solution was cooled in an ice bath and treated dropwise with 16.3 ml of ethyl chloroformate. After stirring at room temperature overnight, the two-phase reaction mixture was diluted with 100 ml of water and extracted with 300 ml of a 1:1 pentane/ether mixture. The extract was washed three times 15 with 0.02 N sodium hydroxide solution, water and then brine. After drying and evaporation, 27.63 g (97%) of the subtitle compound were obtained. NMR (300 MHz, CDCl₃): δ 7.23-7.18 (m, 2H); 7.00 (dt, J=8.4, 2.7, 1H); 4.35 (q, J=7.1, 2H); 20 1.40 (t, J=7.1, 3H).

B. Preparation of (2-chloro-4-fluoro-5-nitrophenyl)- ethyl carbonate

A solution of 27.63 g of (2-chloro-4-fluorophenyl)- 25 ethyl carbonate in 60 ml of dichloromethane was cooled in an ice bath and treated dropwise with 31.86 g of a 1:2 mixture of fuming nitric acid (90%) and concentrated sulfuric acid. The reaction was stirred for 2 hours at room temperature and then cooled with ice and treated with another 4.5 g of the 30 same nitrating mixture. The reaction was stirred overnight at room temperature, poured into 200 ml of ice and water, and extracted twice with dichloromethane. The extracts were

X-12143A

-78-

washed with water and then with brine, dried over magnesium sulfate and concentrated to afford 33.01 g (99%) of the subtitle compound. mp. 50-51 C

Elemental Analyses

5 Calculated: C 41.01; H 2.68; N 5.31; Cl 13.45
 Found: C 41.03; H 2.59; N 5.38; Cl 13.71

C. Preparation of 2-chloro-4-fluoro-5-nitroanisole

A solution of 15.0 g of (2-chloro-4-fluoro-5-nitrophenyl)- ethyl carbonate in 100 ml of dimethyl formamide was treated with 18.6 g of cesium carbonate, 7.1 ml of iodomethane and 7 ml of methanol and stirred overnight at room temperature. The reaction mixture was poured into water and extracted twice with ether. The extracts were washed twice with water and then with brine, dried over magnesium sulfate and concentrated to afford 11.4g of the subtitle compound. mp. 69-70°C Ex. 57, C.

Elemental Analyses

Calculated: C 40.90; H 2.45; N 6.81; Cl 17.25
20 Found: C 41.20; H 2.48; N 6.70; Cl 17.44

D. Preparation of 2-fluoro-5-methoxyaniline

A solution of 5.63 g of 2-chloro-4-fluoro-5-nitroanisole in 90 ml of ethanol and 5 ml of triethylamine was hydrogenated at room temperature under 60 pounds per square inch with 1.0 g of 5% palladium on carbon for four hours. The catalyst was filtered off and the solvent was evaporated. The residue was slurried in chloroform and filtered thourough a plug of silica gel and then evaporated. This residue was chromatographed on silica gel using hexane/chloroform mixtures to afford 2.77 g (72%) of the subtitle compound. mp. 253-254°C. NMR (300 MHz, CDCl₃): δ 6.88 (dd,

X-12143A

-79-

J=10.6, 8.9, 1H); 6.32 (dd, J=7.4, 3.0, 1H); 6.20 (dt, J=8.9, 3.2, 1H); 3.73 (s, 3H); 3.72 (br, 2H).

E. Preparation of N-benzyl-2-fluoro-5-methoxyaniline

5 This procedure was patterned after that of Tietze and Grote, Chem Ber. 126(12), 2733 (1993). A solution of 2.73 g of 2-fluoro-5-methoxyaniline and 2.67 g of benzaldehyde in 48 ml of methanol was treated with 3.43 g of zinc chloride and then cooled in an ice bath. Sodium cyanoborohydride
 10 (1.58 g) was added in small portions over 30 minutes and the reaction was stirred for five hours at room temperature. After evaporation of the solvent, the residue was slurried in 40 ml of 1 N sodium hydroxide solution and then extracted twice with ether. The extracts were washed
 15 with water and then with brine, dried over magnesium sulfate and concentrated. The residue was recrystallized from hexane to afford 2.61 g and the mother liquors were chromatographed on silica gel using 20:1 hexane/ether to afford another 1.4 g of the subtitle compound (90%). mp.

20 56-58°C

Elemental Analyses

Calculated: C 72.71; H 6.10; N 6.06

Found: C 72.51; H 6.06; N 5.99

25 F. Preparation of ethyl 9-benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxylate

A solution of 0.62 g of N-benzyl-2-fluoro-5-methoxyaniline in 20 ml of dry tetrahydrofuran was cooled in an ice bath and treated with 11.3 ml of 0.5 M potassium
 30 bis(trimethylsilyl)amide in toluene. After stirring for 30 minutes, 0.74 g of 2-carboethoxy-6-bromocyclohexanone (Sheehan and Mumaw, JACS, 72, 2127 (1950)) in 4 ml of tetrahydrofuran was added and the reaction was allowed to

X-12143A

-80-

warm slowly to room temperature over two hours. The reaction was quenched with saturated ammonium chloride solution and extracted twice with ether. The extracts were washed with water and then with brine, dried over magnesium sulfate and concentrated. This residue was chromatographed on silica gel using hexane/ ether mixtures to afford 0.796 g (74%) of N-alkylated intermediate diastereomers. This mixture was refluxed in 20 ml of benzene with 0.99 g of zinc chloride overnight. The solvent was evaporated and the residue was partitioned between 25 ml of 1 N HCl and 25 ml of ethyl acetate and then extracted once more with ethyl acetate. The organic layers were washed with water and then brine, dried over magnesium sulfate and concentrated to afford 0.734 g (96%) of the subtitled compound. ESIMS *m/e*

15 382 ($M^{+}+1$)

Elemental Analyses

Calculated: C 72.42; H 6.34; N 3.67
Found: C 72.20; H 6.26; N 3.70

20 G. Preparation of 9-benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxamide

Ethyl 9-benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxylate (0.722 g) was treated similarly as described in Example 49, Part C and chromatographed on silica gel using 1% methanol in dichloromethane to afford 0.482 g (72%) of the subtitle compound. ESIMS *m/e* 353 ($M^{+}+1$)

Elemental Analyses

Calculated: C 71.57; H 6.01; N 7.95
30 Found: C 71.42; H 5.83; N 7.75

X-12143A

-81-

H. Preparation of [9-benzyl-4-carbamoyl-8-fluoro-1,2,3,4-tetrahydrocarbazol-5-yl]oxyacetic acid methyl ester

9-Benzyl-5-methoxy-8-fluoro-1,2,3,4-tetrahydrocarbazole-4-carboxamide (0.170 g) was converted
 5 similarly as described in Example 49, Part D and chromatographed on silica gel using methanol/ 0-1% in dichloromethane to afford 85 mg (50%) of the subtitle compound. mp. 183-185°C

Elemental Analyses

10 Calculated: C 67.31; H 5.65; N 6.82
 Found: C 67.58; H 5.48; N 6.95

I. Preparation of [9-benzyl-4-carbamoyl-8-fluoro-1,2,3,4-tetrahydrocarbazol-5-yl]oxyacetic acid

15 [9-Benzyl-4-carbamoyl-8-fluoro-1,2,3,4-tetrahydrocarbazol-5-yl]oxyacetic acid methyl ester (71 mg) was hydrolyzed similarly as described in Example 50, Part D to afford 65 mg of the title compound. ESIMS *m/e* 397 ($M^{+}+1$), 395 ($M^{+}-1$) NMR (300 MHz, d⁶-DMSO): δ 13.03 (br, 1H); 7.31-7.19 (m, 3H); 6.97 (d, J=7.4, 2H); 6.95 (br, 1H); 6.70 (d, J=3.8, 1H); 6.67 (dd, J=12.4, 3.9, 1H); 6.28 (dd, J=8.5, 2.6, 1H); 5.39 (ABq, 2H); 4.64 (s, 2H); 3.92 (br, 1H); 2.71 (m, 1H); 2.44 (m, 1H); 2.02 (m, 2H); 1.76 (m, 2H).

25 Example 12

Preparation of [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid

A. Preparation of 9-benzyl-5-carbamoyl-4-methoxy-1-chlorocarbazole

30 A solution of 1.0 g of 9-benzyl-5-methoxy-8-methyl-1,2,3,4-tetrahydrocarbazole-4-carboxamide was oxidized

X-12143A

-82-

similarly to Example 51, Part A and chromatographed on silica gel using dichloromethane/ 0-1% methanol to afford 0.66 g (67%) of the subtitle compound. FDMS m/e 364 (M^+)

Elemental Analyses

5 Calculated: C 69.14; H 4.70; N 7.68; Cl 9.72
 Found: C 69.40; H 4.64; N 7.49; Cl 9.98

B. Preparation of 5-carbamoyl-4-hydroxy-1-chlorocarbazole

A solution of 0.66 g of 9-benzyl-5-carbamoyl-4-methoxy-
10 1-chlorocarbazole in 40 ml of dichloromethane was cooled in
an ice bath treated dropwise with 14 ml of 1.0 M boron
tribromide solution in dichloromethane. The reaction was
allowed to warm to room temperature slowly over 2 hours and
then quenched by pouring into ice and then adding 50 ml of 1
15 N HCl. The mixture was extracted with dichloromethane
(3x200 ml) and the extracts were washed with brine, dried
with magnesium sulfate and concentrated. The aqueous layers
exhibited a precipitate and was then extracted twice with
ethyl acetate, washed with brine, dried with magnesium
20 sulfate and concentrated to afford 0.287 g of the subtitle
compound. The first residue was chromatographed on silica
gel using 0.5% methanol in dichloromethane to afford another
93 mg of the subtitle compound. (total yield 80%) ESIMS m/e
259 (M^+-1) NMR (300 MHz, d_6 -DMSO): δ 11.79 (s, 1H); 10.76
25 (s, 1H); 8.87 (br s, 1H); 8.41 (br s, 1H); 7.77 (t, $J=4.6$,
1H); 7.48 (d, $J=4.2$, 2H); 7.34 (d, $J=8.5$, 1H); 6.54 (d,
 $J=8.5$, 1H).

**C. Preparation of [5-carbamoyl-1-chlorocarbazol-4-
30 yl]oxyacetic acid methyl ester**

A solution of 0.28 g of 5-carbamoyl-4-hydroxy-1-
chlorocarbazole in 6 ml of tetrahydrofuran was added to

X-12143A

-83-

0.043 g of sodium hydride (60% in mineral oil) in 1 ml of tetrahydrofuran and stirred for 60 minutes at room temperature. Methyl bromoacetate (0.11 ml) was then added and the reaction was stirred overnight. The reaction
5 mixture was poured into 20 ml of saturated ammonium chloride solution and then extracted twice with ethyl acetate. The extracts were washed with water and then with brine, dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel eluting with chloroform and
10 then 2:1 chloroform/ethyl acetate to afford 0.16 g (45%) of the subtitle compound. ESIMS m/e 333 (M^++1), 335 (M^++3), 331 (M^+-1) NMR (300 MHz, d^6 -DMSO): δ 11.73 (s, 1H); 7.56 (d, J=8.1, 1H); 7.50 (br s, 1H); 7.43-7.35 (m, 2H); 7.18 (br s, 1H); 7.06 (d, J=7.8, 1H); 6.56 (d, J=8.6, 1H); 4.90 (s, 2H);
15 3.70 (s, 3H).

D. Preparation of [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid methyl ester

A solution of 78 mg of [5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid methyl ester in 0.8 ml of dry dimethylformamide was added to 10 mg sodium hydride (60% in mineral oil) in 0.2 ml of dimethylformamide and stirred for 15 minutes. Benzyl bromide (0.031 ml) was then added and the reaction was stirred overnight. The reaction mixture
20 was poured into water and acidified with 1 ml of 1 N HCl solution and extracted twice with ethyl acetate. The extracts were washed with water (3x) and then with brine, dried over magnesium sulfate and concentrated. The residue
25 was chromatographed on silica gel eluting with methanol/0-2% dichloromethane to afford 40 mg of the subtitle compound.
30 ESIMS m/e 423 (M^++1) 425 (M^++3) NMR (300 MHz, $CDCl_3$): δ 7.43-7.22 (m, 7H); 7.06 (d, J=7.3, 2H); 6.51 (d, J=8.6, 1H); 6.05 (s, 2H); 5.80 (br, 2H); 4.88 (s, 2H); 3.83 (s, 3H).

X-12143A


-84-

E. Preparation of [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid

[9-Benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid methyl ester (15 mg) was hydrolyzed similarly as described in Example 50, Part D to afford 14 mg of the title compound. mp. 240-2°C ESIMS *m/e* 409 (M^++1), 411 (M^++3), 407 (M^+-1) NMR (300 MHz, d^6 -DMSO): δ 12.94 (br, 1H); 7.70 (br, 1H); 7.61 (d, $J=8.3$, 1H); 7.43 (t, $J=7.8$, 1H); 7.36 (m, 2H); 7.28-7.19 (m, 3H); 7.13 (d, $J=7.2$, 1H); 6.99 (d, $J=7.4$, 2H); 6.63 (d, $J=8.6$, 1H); 6.08 (s, 2H); 4.83 (s, 2H).

EXAMPLE 13

Preparation of [9-[(Cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid



15

A. 9-[(Cyclohexyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

A 0 °C suspension of 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one (1.0 g, 4.11 mmol), a catalytic amount of NaI (ca. 10 mg) and K₂CO₃ (1.1 g, 8.22 mmol) in 10 mL of DMF was treated with cyclohexylmethyl bromide (0.631 mL, 4.52 mmol). After stirring overnight at ambient temperature, an

X-12143A

-85-

additional 0.63 mL cyclohexylmethylbromide was added, and the resulting mixture was heated at 60 °C for 3 hours. The mixture was poured into H₂O (30 mL) and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with H₂O (4 x 50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by radial chromatography on silica gel (elution with a gradient of 20% to 40% EtOAc/hexanes) to afford 1.36 g (4.01 mmol; 97%) of 9-[(cyclohexyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one as a white foam. IR (CHCl₃, cm⁻¹) 3011, 2932, 2857, 1725, 1649, 1469, 1446, 1288 and 1120. MS (ES) m/e 340 (M+1), 453 (M+AcO⁻). FAB HRMS m/e, Calcd for C₂₁H₂₆NO₃: 340.1913. Found: 340.1916 (M+1).

Elemental Analyses for C₂₁H₂₅NO₃:

Calculated: C, 74.31; H, 7.42; N, 4.13.
Found: C, 72.65; H, 7.39; N, 4.70.

B. 9-[(Cyclohexyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

A solution of 9-[(cyclohexyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (1.16 g, 3.42 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (853 mg, 3.76 mmol) in 20 mL of toluene was heated at 80 °C for 3 hours. The mixture was purified directly by column chromatography on silica gel (elution with CH₂Cl₂) to afford 259 mg (0.768 mmol; 22%) of 9-[(cyclohexyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a yellow oil which slowly solidified. MS (ES) m/e 338 (M+1), 336 (M-1).

Elemental Analyses for C₂₁H₂₃NO₃:

Calculated: C, 74.75; H, 6.87; N, 4.15.
Found: C, 74.95; H, 6.99; N, 4.42.

X-12143A

-86-

C. 9-[(Cyclohexyl)methyl]-4-hydroxy-5-carbamoyl carbazole

A solution of 9-[(cyclohexyl)methyl]-4-hydroxy-5-carbamethoxy carbazole (205 mg, 0.608 mmol) in 5 mL of THF and 20 mL of concentrated aqueous ammonium hydroxide was
5 treated with a stream of NH₃ gas to ensure saturation. The reaction vessel was capped, and the mixture was heated at 35 °C with stirring until tlc indicated complete consumption of starting material (20 hrs). The THF was evaporated, and the aqueous layer was filtered. The green solid precipitate was
10 dissolved in THF and purified by radial chromatography on silica gel (elution with CH₂Cl₂). The resultant foam was triturated with ether to afford 138 mg (70%) of the title compound as an off-white solid. IR (KBr, cm⁻¹) 3418, 3200, 3131, 1629, 1600, 1443, 1261, 778. ¹FAB HRMS m/e, Calcd for
15 C₂₀H₂₃N₂O₂: 323.1760. Found: 323.1760 (M+1).

D. [9-[(Cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, methyl ester

A mixture of 9-[(cyclohexyl)methyl]-4-hydroxy-5-carbamoyl carbazole (60 mg, 0.186 mmol) and Cs₂CO₃ (150 mg; 0.460 mmol) in 2 mL of DMF was treated with methyl bromoacetate (0.023 mL; 0.242 mmol). The reaction was stirred for 2 hours at ambient temperature, then it was diluted with EtOAc and H₂O (10 mL each). The aqueous layer was saturated with solid NaCl and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with H₂O (2 x 25 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. Purification of the crude residue by flash chromatography on silica gel (elution with a gradient
25 of 0% to 90% EtOAc/hexanes) followed by trituration with Et₂O/EtOAc afforded 45 mg (0.114 mmol; 61%) of title compound as an off-white solid. MS (ES) m/e 395 (M+1), 378 (M+H-NH₃), 453 (M+AcO⁻).

X-12143A

-87-

Elemental Analyses for $C_{23}H_{26}N_2O_4 \cdot 0.3H_2O$:

Calculated: C, 69.08; H, 6.71; N, 7.01.

Found: C, 69.13; H, 6.71; N, 7.09.

5 E. [9-[(Cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid

A slurry of [9-[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, methyl ester (20 mg, 0.051 mmol) in 0.3 mL of THF and 0.1 mL of MeOH was treated 10 with 0.1 mL of 1 N aq LiOH (0.1 mmol), and the mixture stirred at room temperature for 2 h. The reaction was acidified with 0.2 N HCl, and the organics were removed *in vacuo*. The white precipitate was filtered away from the aqueous layer and rinsed with Et_2O to afford 16 mg (0.042 15 mmol; 83%) the title acid as a white powder. MS (ES) m/e 381 ($M+1$), 364 ($M+H-NH_3$), 379 ($M-1$).

Elemental Analyses for $C_{22}H_{24}N_2O_4$:


Calculated: C, 69.46; H, 6.36; N, 7.36.

Found: C, 69.34; H, 6.35; N, 7.29.

20

EXAMPLE 14

Preparation of [9-[(Cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid



X-12143A

-88-

A. 9-[(Cyclopentyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one

A suspension of 5-carbomethoxy-1,2-dihydro-9H-carbazol-4(3H)-one (820 g, 3.37 mmol), a catalytic amount of NaI (ca. 5 10 mg) and K₂CO₃ (930 mg, 6.74 mmol) in 6 mL of DMF was treated with cyclopentylmethyl chloride (*JOC*, 1964, 29, 421-423; 400 mg, 3.37 mmol). After stirring overnight at ambient temperature, an additional 800 mg of cyclopentylmethyl chloride and 1 g of NaI were added, and 10 the resulting mixture was heated at 80 °C overnight. An additional 800 mg of cyclopentylmethyl chloride and 2.2 g of Cs₂CO₃ were added, and the reaction mixture was heated at 80 °C for 24 h. An additional 1.6 g of cyclopentylmethyl chloride was added, and the reaction mixture was heated at 15 80 °C for 3 d. The mixture was poured into H₂O (30 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by radial chromatography on silica gel (elution with gradient of 10% 20 to 40% EtOAc/hexanes) to afford 775 mg (2.38 mmol; 71%) of 9-[(cyclopentyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one as a brown foam. MS (ES) m/e 326 (M+1), 384 (M+AcO⁻).

Elemental Analyses for C₂₀H₂₃NO₃:

25 Calculated: C, 73.82; H, 7.12; N, 4.30.
Found: C, 74.12; H, 7.21; N, 4.45.

B. 9-[(Cyclopentyl)methyl]-4-hydroxy-5-carbomethoxy carbazole

30 A solution of 9-[(cyclopentyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one (730 mg, 2.24 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (560 mg, 2.47 mmol) in 20 mL of toluene was heated at 80 °C for 3 hours. The

X-12143A

-89-

mixture was purified directly by column chromatography on silica gel (elution with CH₂Cl₂) to afford 140 mg (0.433 mmol; 19%) of 9-[(cyclopentyl)methyl]-4-hydroxy-5-carbomethoxy carbazole as a yellow oil which slowly solidified. MS (ES) m/e 324 (M+1), 322 (M-1).

Elemental Analyses for C₂₀H₂₁NO₃·0.3H₂O:

Calculated: C, 73.06; H, 6.62; N, 4.26.

Found: C, 73.19; H, 6.44; N, 4.40.

10 C. 9-[(Cyclopentyl)methyl]-4-hydroxy-5-carbamoyl carbazole
A solution of 9-[(cyclopentyl)methyl]-4-hydroxy-5-carbomethoxy carbazole (110 mg, 0.34 mmol) in 3 mL of THF and 20 mL of concentrated aqueous ammonium hydroxide was treated with a stream of NH₃ gas to ensure saturation. The reaction vessel was capped, and the mixture heated to 35 °C with stirring until tlc indicated complete consumption of starting material (20 h). The THF was evaporated, and the aqueous layer was filtered. The resultant solid was triturated with ether to afford 50 mg (0.162; 48%) of the title compound as a greenish-white solid. IR (KBr, cm⁻¹) 3416, 3199, 3126, 1630, 1599. 1442, 1262, 778. ¹FAB HRMS m/e, Calcd for C₂₀H₂₁N₂O₂: 309.1603. Found: 309.1607 (M+1).'

25 D. [9-[(Cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, methyl ester
A mixture of 9-[(cyclopentyl)methyl]-4-hydroxy-5-carbamoyl carbazole (45 mg, 0.146 mmol) and Cs₂CO₃ (120 mg; 0.365 mmol) in 2 mL of DMF was treated with methyl bromoacetate (0.018 mL; 0.19 mmol). The reaction was stirred for 2 hours at ambient temperature, then it was diluted with EtOAc and H₂O (10 mL each). The aqueous layer was saturated with solid NaCl extracted with EtOAc (2 x 10 mL). The

X-12143A

-90-

combined organic layers were washed with H₂O (2 x 25 mL), dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Purification of the crude residue by flash chromatography on silica gel (elution with a gradient of 0% 5 to 100% EtOAc/hexanes) followed by trituration with Et₂O/EtOAc afforded 26 mg (0.0683 mmol; 47%) of title compound as a tan solid. MS (ES) m/e 381 (M+1), 364 (M+H-NH₃), 439 (M+AcO⁻).

Elemental Analyses for C₂₃H₂₆N₂O₄ · 0.1H₂O:

10 Calculated: C, 69.13; H, 6.38; N, 7.33.
 Found: C, 68.99; H, 6.39; N, 7.41.

E. [9-[(Cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid

15 A slurry of [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, methyl ester (20 mg, 0.065 mmol) in 0.3 mL of THF and 0.1 mL of MeOH was treated with 0.1 mL of 1 N aq LiOH (0.1 mmol), and the mixture stirred at room temperature for 2 hours. The reaction was 20 acidified with 0.2 N HCl, and the organics were removed *in vacuo*. The white precipitate was filtered away from the aqueous layer and rinsed with Et₂O to afford 15 mg (0.0409 mmol; 63%) the title acid as a white powder. MS (ES) m/e 367 (M+1), 350 (M+H-NH₃), 365 (M-1).

25 Elemental Analyses for C₂₁H₂₂N₂O₄ · 0.3H₂O:

 Calculated: C, 67.84; H, 6.13; N, 7.53.
 Found: C, 67.73; H, 5.97; N, 7.70.

30 The compounds described herein are believed to achieve their beneficial therapeutic action principally by direct inhibition of human sPLA₂, and not by acting as antagonists for arachidonic acid, nor other active agents

X-12143A

-91-

below arachidonic acid in the arachidonic acid cascade, such as 5-lipoxygenases, cyclooxygenases, etc.

The method of the invention for inhibiting sPLA₂ mediated release of fatty acids comprises contacting sPLA₂ with an

5 therapeutically effective amount of a compound of Formula (I) selected from the group consisting [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid, {9-[{(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[{(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[{(3-chlorophenyl)methyl]-5-

10 carbamoylcarbazol-4-yl}oxyacetic acid, {9-[{(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[{(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[{(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[{(3-trifluoromethoxyphenyl)methyl]-5-

15 carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid, [9-[{(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, [9-[{(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid or its pharmaceutically acceptable salt.

The compounds of the invention may be used in a method of treating a mammal (e.g., a human) to alleviate the pathological effects of septic shock, adult

25 respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, and rheumatoid arthritis; wherein the method comprises administering to the mammal a compound of formula (I) in a therapeutically effective amount. A "therapeutically effective" amount is

30 an amount sufficient to inhibit sPLA₂ mediated release of fatty acid and to thereby inhibit or prevent the arachidonic acid cascade and its deleterious products. The therapeutic amount of compound of the invention needed to inhibit sPLA₂ may be readily determined by taking a

X-12143A

-92-

sample of body fluid and assaying it for sPLA₂ content by conventional methods.

Throughout this document, the person or animal to be treated will be described as a "mammal", and it will 5 be understood that the most preferred subject is a human. However it must be noted that the study of adverse conditions of the central nervous system in non-human animals is only now beginning, and that some instances of such treatments are coming into use. Accordingly, use of 10 the present compounds in non-human animals is contemplated. It will be understood that the dosage ranges for other animals will necessarily be quite different from the doses administered to humans, and accordingly that the dosage ranges described be 15 recalculated. For example, a small dog may be only 1/10th of a typical human's size, and it will therefore be necessary for a much smaller dose to be used. The determination of an effective amount for a certain non-human animal is carried out in the same manner described 20 below in the case of humans, and veterinarians are well accustomed to such determinations.

As previously noted the compounds of this invention are useful for inhibiting sPLA₂ mediated release 25 of fatty acids such as arachidonic acid. By the term, "inhibiting" is meant the prevention or therapeutically significant reduction in release of sPLA₂ initiated fatty acids by the compounds of the invention. By "pharmaceutically acceptable" it is meant the carrier, 30 diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

In general, the compounds of the invention are most desirably administered at a dose that will generally

X-12143A

-93-

afford effective results without causing any serious side effects and can be administered either as a single unit dose, or if desired, the dosage may be divided into convenient subunits administered at suitable times
5 throughout the day.

The specific dose of a compound administered according to this invention to obtain therapeutic or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including,
10 for example, the route of administration, the age, weight and response of the individual patient, the condition being treated and the severity of the patient's symptoms. Typical daily doses will contain a non-toxic dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight
15 of an active compound of this invention.

Preferably the pharmaceutical formulation is in unit dosage form. The unit dosage form can be a capsule or tablet itself, or the appropriate number of any of these. The quantity of active ingredient in a unit dose of
20 composition may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The
25 dosage will also depend on the route of administration.

A "chronic" condition means a deteriorating condition of slow progress and long continuance. As such, it is treated when it is diagnosed and continued throughout the course of the disease. An "acute"
30 condition is an exacerbation of short course followed by a period of remission. In an acute event, compound is administered at the onset of symptoms and discontinued when the symptoms disappear.

X-12143A

-94-

Pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis and rheumatoid arthritis may occur as an acute event or a chronic event. Thus, the treatment of these conditions contemplates both acute and 5 chronic forms. Septic shock and adult respiratory distress, on the other hand, are acute conditions treated when diagnosed.

The compound can be administered by a variety of routes including oral, aerosol, rectal, transdermal, 10 subcutaneous, intravenous, intramuscular, and intranasal.

Pharmaceutical formulations of the invention are prepared by combining (e.g., mixing) a therapeutically effective amount of the compounds of the invention together with a pharmaceutically acceptable carrier or 15 diluent therefor. The present pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.

In making the compositions of the present invention, the active ingredient will usually be admixed 20 with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, or can be in the form of 25 tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing, for example, up to 10% by weight of the active compound. The compounds of the present invention are preferably formulated prior to 30 administration.

For the pharmaceutical formulations any suitable carrier known in the art can be used. In such a formulation, the carrier may be a solid, liquid, or mixture of a solid and a liquid. Solid form formulations

X-12143A

-95-

include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and
5 encapsulating material.

Tablets for oral administration may contain suitable excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, together with disintegrating agents, such as maize, starch, or alginic
10 acid, and/or binding agents, for example, gelatin or acacia, and lubricating agents such as magnesium stearate, stearic acid, or talc.

In powders the carrier is a finely divided solid which is in admixture with the finely divided active
15 ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about 1 to about 99 weight percent of the active
20 ingredient which is the novel compound of this invention. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa
25 butter.

Sterile liquid form formulations include suspensions, emulsions, syrups and elixirs.

The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such
30 as sterile water, sterile organic solvent or a mixture of both. The active ingredient can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol. Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or

X-12143A

-96-

sodium carboxymethyl cellulose solution or in a suitable oil.

The following pharmaceutical formulations 1 through 8 are illustrative only and are not intended to limit the scope of the invention in any way. "Active ingredient", refers to a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

Formulation 1

10 Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Compound of Example 1	250
Starch, dried	200
Magnesium stearate	<u>10</u>
Total	460 mg

Formulation 2

15 A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
Compound of Example 2	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	<u>5</u>
Total	665 mg

The components are blended and compressed to form tablets each weighing 665 mg

X-12143A

-97-

Formulation 3

An aerosol solution is prepared containing the following components:

	<u>Weight</u>
Compound of Example 3	0.25
Ethanol	25.75
Propellant 22 (Chlorodifluoromethane)	<u>74.00</u>
Total	100.00

5

The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container
 10 and diluted with the remainder of the propellant. The valve units are then fitted to the container.

Formulation 4

15 Tablets, each containing 60 mg of active ingredient, are made as follows:

Compound of Example 4	60 mg
Starch	45 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	<u>1 mg</u>
Total	150 mg

X-12143A

-98-

The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder,
5 and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are
10 then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation 5

15 Capsules, each containing 80 mg of active ingredient, are made as follows:

Compound of Example 5	80 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	<u>2 mg</u>
Total	200 mg

20 The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

X-12143A

-99-

Formulation 6

Suppositories, each containing 225 mg of active ingredient, are made as follows:

Compound of Example 6	225 mg
-----------------------	--------

Saturated fatty acid glycerides	<u>2,000 mg</u>
Total	2,225 mg

5

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

10

Formulation 7

Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:

15

Compound of Example 7	50 mg
-----------------------	-------

Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 ml
Benzoic acid solution	0.10 ml
Flavor	q.v.
Color	q.v.
Purified water to total	5 ml

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

20

X-12143A

-100-

Formulation 8

An intravenous formulation may be prepared as follows:

5

Compound of Example 8 100 mg

Isotonic saline 1,000 ml

The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute.

10

Assay ExperimentsAssay Example 1

The following chromogenic assay procedure was used to identify and evaluate inhibitors of recombinant human secreted phospholipase A₂. The assay described herein has been adapted for high volume screening using 96 well microtiter plates. A general description of this assay method is found in the article, "Analysis of Human Synovial Fluid Phospholipase A₂ on Short Chain Phosphatidylcholine-Mixed Micelles: Development of a Spectrophotometric Assay Suitable for a Microtiterplate Reader", by Laure J. Reynolds, Lori L. Hughes, and Edward A Dennis, Analytical Biochemistry, 204, pp. 190-197, 1992 (the disclosure of which is incorporated herein by reference):

Reagents:

REACTION BUFFER -

CaCl₂.2H₂O (1.47 g/L)
KCl (7.455 g/L)
Bovine Serum Albumin (fatty acid free) (1 g/L)

X-12143A

-101-

(Sigma A-7030, product of Sigma Chemical Co.
St. Louis MO, USA)
TRIS HCl (3.94 g/L)
pH 7.5 (adjust with NaOH)

5

ENZYME BUFFER -

0.05 NaOAc.3H₂O, pH 4.5
0.2 NaCl
Adjust pH to 4.5 with acetic acid

10

DTNB -

5,5'-dithiobis-2-nitrobenzoic acid

RACEMIC DIHEPTANOYL THIO - PC

15 racemic 1,2-bis(heptanoylthio)-1,2-dideoxy-sn-glycero-3-phosphorylcholine
TRITON X-100™ prepare at 6.249 mg/ml in reaction buffer to equal 10uM

TRITON X-100™ is a polyoxy ethylene non-ionic detergent supplied by Pierce Chemical Company, 3747 N. Meridian Road, Rockford, Illinois 61101.

25 REACTION MIXTURE -

A measured volume of racemic dipheptanoyl thio PC supplied in chloroform at a concentration of 100 mg/ml is taken to dryness and redissolved in 10 millimolar TRITON X-100™ nonionic detergent aqueous solution.

30 Reaction Buffer is added to the solution, then DTNB to give the Reaction Mixture.

The reaction mixture thus obtained contains 1mM diheptanoyl thio-PC substrate, 0.29 mM Triton X-100™

X-12143A

-102-

detergent, and 0.12 mM DTMB in a buffered aqueous solution at pH 7.5.

Assay Procedure:

- 5 1. Add 0.2 ml reaction mixture to all wells;
2. Add 10 μ l test compound (or solvent blank) to appropriate wells, mix 20 seconds;
3. Add 50 nanograms of sPLA₂ (10 microliters) to appropriate wells;
- 10 4. Incubate plate at 40°C for 30 minutes;
5. Read absorbance of wells at 405 nanometers with an automatic plate reader.

All compounds were tested in triplicate.

Typically, compounds were tested at a final concentration 15 of 5 μ g/ml. Compounds were considered active when they exhibited 40% inhibition or greater compared to uninhibited control reactions when measured at 405 nanometers. Lack of color development at 405 nanometers evidenced inhibition. Compounds initially found to be 20 active were reassayed to confirm their activity and, if sufficiently active, IC₅₀ values were determined.

Typically, the IC₅₀ values (see, Table I, below) were determined by diluting test compound serially two-fold such that the final concentration in the reaction ranged 25 from 45 μ g/mL to 0.35 μ g/ml. More potent inhibitors required significantly greater dilution. In all cases, % inhibition measured at 405 nanometers generated by enzyme reactions containing inhibitors relative to the uninhibited control reactions was determined. Each sample 30 was titrated in triplicate and result values were averaged for plotting and calculation of IC₅₀ values. IC₅₀ were determined by plotting log concentration versus inhibition values in the range from 10-90% inhibition.

X-12143A

-103-

Compounds of the instant invention were tested in Assay Example 1 and were found to be effective at concentrations of less than 100 μ M.

5

Assay Example 2Method:

Male Hartley strain guinea pigs (500-700g) were killed by cervical dislocation and their heart and lungs removed intact and placed in aerated (95% O₂:5% CO₂) Krebs buffer. Dorsal pleural strips (4x1x25mm) were dissected from intact parenchymal segments (8x4x25mm) cut parallel to the outer edge of the lower lung lobes. Two adjacent pleural strips, obtained from a single lobe and representing a single tissue sample, were tied at either end and independently attached to a metal support rod. One rod was attached to a Grass force-displacement transducer Model FTO3C, product of Grass Medical Instruments Co., Quincy, MA, USA). Changes in isometric tension were displayed on a monitor and thermal recorder (product of Modular Instruments, Malvern, PA). All tissues were placed in 10 ml jacketed tissue baths maintained at 37°C. The tissue baths were continuously aerated and contained a modified Krebs solution of the following composition (millimolar) NaCl, 118.2; KCl, 4.6; CaCl₂·2H₂O, 2.5; MgSO₄·7H₂O, 1.2; NaHCO₃, 24.8; KH₂PO₄, 1.0; and dextrose, 10.0. Pleural strips from the opposite lobes of the lung were used for paired experiments. Preliminary data generated from tension/response curves demonstrated that resting tension of 800mg was optimal. The tissues were allowed to equilibrate for 45 min. as the bath fluid was changed periodically.

X-12143A

-104-

Cumulative concentration-response curves:

Initially tissues were challenged 3 times with KCl (40 mM) to test tissue viability and to obtain a consistent response. After recording the maximal response 5 to KCl, the tissues were washed and allowed to return to baseline before the next challenge. Cumulative concentration-response curves were obtained from pleural strips by increasing the agonist concentration (sPLA₂) in the tissue bath by half-log₁₀ increments while the 10 previous concentration remained in contact with the tissues (Ref.1, supra.). Agonist concentration was increased after reaching the plateau of the contraction elicited by the preceding concentration. One concentration-response curve was obtained from each 15 tissue. To minimize variability between tissues obtained from different animals, contractile responses were expressed as a percentage of the maximal response obtained with the final KCl challenge. When studying the effects of various drugs on the contractile effects of sPLA₂, the 20 compounds and their respective vehicles were added to the tissues 30 minutes prior to starting the sPLA₂ concentration-response curves.

Statistical analysis:

25 Data from different experiments were pooled and presented as a percentage of the maximal KCl responses (mean \pm S.E.). To estimate the drug induced rightward shifts in the concentration response curves, the curves were analyzed simultaneously using statistical nonlinear 30 modeling methods similar to those described by Waud (1976), Equation 26, p. 163, (Ref.2). The model includes four parameters: the maximum tissue response which was assumed the same for each curve, the ED₅₀ for the control curve, the steepness of the curves, and the pA₂, the

X-12143A

-105-

concentration of antagonist that requires a two-fold increase in agonist to achieve an equivalent response. The Schild slope was determined to be 1, using statistical nonlinear modeling methods similar to those described by

5 Waud (1976), Equation 27, p. 164 (Ref. 2). The Schild slope equal to 1 indicates the model is consistent with the assumptions of a competitive antagonist; therefore, the pA₂ may be interpreted as the apparent K_B, the dissociation constant of the inhibitor.

10 To estimate the drug-induced suppression of the maximal responses, sPLA₂ responses (10 ug/ml) were determined in the absence and presence of drug, and percent suppression was calculated for each pair of tissues. Representative examples of inhibitory activities
15 are presented in Table 2, below.

Ref. 1 - Van, J.M.: Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. Ther., 143: 299-330,
20 1963.

Ref. 2 - Waud, D.: Analysis of dose-response relationships. in Advances in General and Cellular Pharmacology eds Narahashi, Bianchi 1:145-178, 1976.

25 Compounds of the instant invention were tested in Assay Example 2 and were found to be effective at concentrations below 20 μ M.

X-12143A

-106-

Assay Example 3
sPLA₂ Transgenic Mice Assay

Materials & Methods

5 The mice utilized in these studies were mature, 6-8 month old, ZnSO₄-stimulated, hemizygous line 2608^a transgenic mice (Fox et. al. 1996). Transgenic mice from this line express human sPLA₂ in the liver and other tissues and typically achieve levels of human sPLA₂ in
10 their circulation of approximately 173 ± 10 ng/ml when maximally stimulated with ZnSO₄ (Fox, et al. 1996). The mice were housed under constant humidity and temperature and received food and water ad libitum. Animal room lighting was maintained on a 12-hour light/dark cycle and
15 all experiments were performed at the same time of the day during the early morning light period.

For intravenous testing, compounds or vehicle were administered as an IV bolus via the tail vein in a volume of 0.15 ml. Vehicle consisted of 1-5% dimethylsulfoxide,
20 1-5% ethanol and 10-30% polyethylene glycol 300 in H₂O; the concentrations of these ingredients were adjusted according to the solubility of the compound. Mice were bled retro-orbitally prior to drug or vehicle administration and 30 minutes, 2 and 4 hours thereafter.
25 Three to six mice were used for each dose. PLA₂ catalytic activity in the serum was assayed with a modified phosphatidylcholine/deoxycholine mixed micelle assay (Fox, et al. 1996, Schadlich, et al., 1987) utilizing 3 mM sodium deoxycholate and 1 mM 1-palmitoyl-2-oleoyl-sn-
30 glycero-3-phosphocholine.

For oral testing, compounds were dissolved in 1-5% ethanol/10-30% polyethylene glycol 300 in H₂O or were suspended in 5% dextrose in H₂O and administered by oral

X-12143A

-107-

gavage. Serum was prepared from retro-orbital blood and assayed for PLA₂ catalytic activity as above.

References

- 5 Fox, N., M. Song, J. Schrementi, J. D. Sharp, D. L. White, D. W. Snyder, L. W. Hartley, D. G. Carlson, N. J. Bach, R. D. Dillard, S. E. Draheim, J. L. Bobbitt, L. Fisher and E. D. Mihelich. 1996.
Eur. J. Pharmacol. 308: 195.

10

- Schadlich, H.R., M. Buchler, and H. G. Beger, 1987, J. Clin. Chem. Clin. Biochem. 25, 505.

15

Compounds of the instant invention were tested in Assay Example 3 and were found to be effective.

20

While the present invention has been illustrated above by certain specific embodiments, it is not intended that these specific examples should limit the scope of the invention as described in the appended claims.

X-12143A

-108-

Claims

1. A compound selected from the group consisting of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid, {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, {9-[(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt, [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid, [9-[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid, and [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

2. A compound of **Claim 1** which is {9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

3. A compound of **Claim 1** which is of [9-benzyl-5-carbamoyl-1-fluorocarbazol-4-yl]oxyacetic acid or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

4. A compound of **Claim 1** which is {9-[(3-fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid or a pharmaceutically acceptable racemate, solvate,

X-12143A

-109-

tautomer, optical isomer, prodrug derivative or salt, thereof.

5. A compound of **Claim 1** which is {9-[(3-chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

10 6. A compound of **Claim 1** which is {9-[(3-trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

15 7. A compound of **Claim 1** which is {9-[(2-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

20 8. A compound of **Claim 1** which is {9-[(3-methylphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

25 9. A compound of **Claim 1** which is {9-[(3-trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid, sodium salt or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

X-12143A

-110-

10. A compound of **Claim 1** which is [9-benzyl-5-carbamoyl-1-chlorocarbazol-4-yl]oxyacetic acid or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

5

11. A compound of **Claim 1** which is [9-[(cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

10

12. A compound of **Claim 1** which is [9-[(cyclopentyl)methyl]-5-carbamoylcarbazol-4-yl]oxyacetic acid or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

15

13. A compound as claimed in any one of **Claims 1 to 12** wherein the prodrug derivative is a methyl, ethyl, propyl, isopropyl, butyl, morpholinoethyl or diethylglycolamide ester.

20

14. A compound as claimed in any one of **Claims 1 to 12** wherein the salt is sodium.

25

15. A pharmaceutical formulation comprising a compound as claimed in any one of **Claims 1 to 12** together with a pharmaceutically acceptable carrier or diluent therefor.

30

16. A pharmaceutical formulation adapted for the treatment of a condition associated with inhibiting sPLA₂, containing a compound as claimed in any one of

X-12143A

-111-

Claims 1 to 12 together with a pharmaceutically acceptable carrier or diluent therefor.

17. A method of selectively inhibiting sPLA₂ in a
5 mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of any one of **Claims 1 to 12**.

18. A method of **Claim 17** wherein the mammal is
10 a human.

19. A method of alleviating the pathological effects of sPLA₂ related diseases which comprises administering to a mammal in need of such treatment a compound as claimed in any one of **Claims 1 to 12** in an amount sufficient to inhibit sPLA₂ mediated release of fatty acid and to thereby inhibit or prevent the arachidonic acid cascade and its deleterious products.

20 20. The use of a compound of formula I as claimed in any one of **Claims 1 to 12** for the manufacture of a medicament for alleviating the pathological effects of sPLA₂ related diseases which comprises administering to a mammal in need of such treatment a compound of formula I.

21. A method of inhibiting sPLA₂ which comprises contacting the sPLA₂ with a compound as claimed in any one of **Claims 1 to 12**.

30 22. A method of treating sepsis, septic shock, rheumatoid arthritis, osteoarthritis, stroke, apoptosis, asthma, chronic bronchitis, acute bronchitis, cystic fibrosis, inflammatory bowel disease, or pancreatitis which

X-12143A

-112-

comprises administering to a subject in need of such treatment, a therapeutically effective amount of a compound as claimed in any one of **Claims 1 to 12.**

- 5 23. A method of **Claim 21** of alleviating the pathological effects of sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis,
10 chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathis, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathic spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy,
15 infectious or post-infectious arthritis, gonococcal arthritis, Tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with "vasculitic syndromes", polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's
20 granulomatosis, polymyalgia rheumatica, joint cell arteritis, calcium crystal deposition arthropathis, pseudo gout, non-articular rheumatism, bursitis, tenosynovitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury (typing), miscellaneous forms of
25 arthritis, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis associated with certain diseases, surcrostosis, hemochromatosis, sickle cell disease
30 and other hemoglobinopathies, hyperlipoproteinemia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythematosus, or relapsing polychondritis; and related diseases.

- 113 -

24. The use of a therapeutically effective amount of a compound of any one of **Claims 1 to 12** for selectively inhibiting $sPLA_2$ in a mammal.

5 25. The use of **Claim 24** wherein the mammal is a human.

10 26. The use of a compound as claimed in any one of **Claims 1 to 12** in an amount sufficient to inhibit $sPLA_2$ mediated release of fatty acid and to thereby inhibit or prevent the arachidonic acid cascade and its deleterious products for alleviating the pathological effects of $sPLA_2$ related diseases in a mammal.

15 27. The use of a compound as claimed in any of **Claims 1 to 12** for inhibiting $sPLA_2$ by contacting the $sPLA_2$ with a compound as claimed in any one of **Claims 1 to 12**.

20 28. The use of a therapeutically effective amount of a compound as claimed in any one of **Claims 1 to 12** for treating sepsis, septic shock, rheumatoid arthritis, osteoarthritis, stroke, apoptosis, asthma, chronic bronchitis, acute bronchitis, cystic fibrosis, 25 inflammatory bowel disease, or pancreatitis in a subject in need of such treatment.

- 114 -

29. The use of Claim 27 for alleviating the pathological effects of sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathis, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathic spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infectious arthritis, gonococcal arthritis, Tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with "vasculitic syndromes", polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgia rheumatica, joint cell arteritis, calcium crystal deposition arthropathis, pseudo gout, non-articular rheumatism, bursitis, tenosynovitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury (typing), miscellaneous forms of arthritis, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis associated with certain diseases, surcoiosis, hemochromatosis, sickle cell disease and other hemoglobinopathies, hyperlipoproteinemia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythematosis, or relapsing polychondritis; and related diseases.